Howard L. Weiner | Academic Influence

Howard L. Weiner's AcademicInfluence.com Rankings

Howard L. Weiner

Medical

#249

World Rank

#373

Historical Rank

#115

USA Rank

Neurology

#16

World Rank

#39

Historical Rank

#7

USA Rank

medical Degrees

Howard L. Weiner

Biology

#1764

World Rank

#2868

Historical Rank

#845

USA Rank

Immunology

#51

World Rank

#56

Historical Rank

#20

USA Rank

Neuroscience

#144

World Rank

#152

Historical Rank

#63

USA Rank

biology Degrees

Download Badge

Medical
Biology

Howard L. Weiner's Degrees

Doctorate Medicine Harvard University

Why Is Howard L. Weiner Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Howard L. Weiner is an American neurologist, neuroscientist and immunologist who is also a writer and filmmaker. He performs clinical and basic research focused on multiple sclerosis and other neurologic diseases such as Alzheimer's disease and Lou Gehrig's disease . His work also focuses on autoimmune diseases such as diabetes. Weiner is the Robert L. Kroc Professor of Neurology at Harvard Medical School, director of the Brigham MS Center at the Brigham and Women's Hospital and co-director of the Ann Romney Center for Neurologic Diseases established in 2014, at the Brigham and Women's Hospital in Boston, Massachusetts.

(See a Problem?)

Howard L. Weiner's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells (2006) (6954)
Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. (1994) (2128)
Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis (2004) (1868)
B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy (1995) (1863)
Identification of a Unique TGF-β Dependent Molecular and Functional Signature in Microglia (2013) (1853)
The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. (2017) (1367)
Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor (2008) (1082)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial (2012) (1044)
Induction and mechanism of action of transforming growth factor‐β‐secreting Th3 regulatory cells (2001) (983)
Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. (1994) (937)
T-cell recognition of an immuno-dominant myelin basic protein epitope in multiple sclerosis (1990) (915)
CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. (1999) (901)
Oral tolerance. (1994) (853)
Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. (1983) (833)
Oral tolerance: immune mechanisms and treatment of autoimmune diseases. (1997) (832)
Alterations of the human gut microbiome in multiple sclerosis (2016) (814)
A dominant function for interleukin 27 in generating interleukin 10–producing anti-inflammatory T cells (2007) (809)
Oral tolerance (2011) (808)
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci (2009) (799)
Myelin Oligodendrocyte Glycoprotein–specific T Cell Receptor Transgenic Mice Develop Spontaneous Autoimmune Optic Neuritis (2003) (785)
Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. (1992) (751)
Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain (1992) (735)
MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-α–PU.1 pathway (2011) (714)
Peripheral deletion of antigen-reactive T cells in oral tolerance (1995) (684)
Differential roles of microglia and monocytes in the inflamed central nervous system (2014) (674)
Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. (1994) (658)
Resistance to Experimental Autoimmune Encephalomyelitis in Mice Lacking the Cc Chemokine Receptor (Ccr2) (2000) (632)
Effects of oral administration of type II collagen on rheumatoid arthritis. (1993) (620)
Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. (1993) (598)
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility (2019) (589)
Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis (1994) (559)
IL-10 is critical in the regulation of automimmune encephalomyelitis as demonstrated by studies of IL-10 and IL-4 deficient and transgenic mice (1998) (542)
Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. (1996) (513)
The Host Shapes the Gut Microbiota via Fecal MicroRNA. (2016) (493)
Multiple Sclerosis: Mechanisms and Immunotherapy (2018) (490)
Activation of CD25+CD4+ Regulatory T Cells by Oral Antigen Administration1 (2001) (489)
The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. (2001) (486)
Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis (1999) (484)
Loss of suppressor T cells in active multiple sclerosis. Analysis with monoclonal antibodies. (1980) (438)
Antigen-driven bystander suppression after oral administration of antigens (1991) (428)
Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. (2001) (418)
Microglial signatures and their role in health and disease (2018) (417)
Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein. (1990) (407)
Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. (2012) (404)
Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions (1986) (402)
Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments (1987) (395)
Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell–like and Foxp3+ regulatory T cells (2010) (392)
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring (2007) (391)
Loss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis (2017) (390)
IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. (2004) (381)
A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. (1987) (378)
An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis (2010) (365)
Protective Autoimmunity Is a Physiological Response to CNS Trauma (2001) (349)
Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. (1991) (343)
The Aryl hydrocarbon Receptor (AhR) interacts with c-Maf to promote the differentiation of IL-27-induced regulatory type 1 (TR1) cells (2010) (343)
Nasal administration of amyloid‐β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease (2000) (337)
Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation (2014) (336)
Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome. (1994) (334)
Oral tolerance: mechanisms and therapeutic applications. (1999) (332)
Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. (1997) (332)
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial (2016) (331)
Human polymorphism at microRNAs and microRNA target sites. (2013) (330)
In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. (1985) (324)
The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease? (2009) (323)
Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. (2015) (321)
Disease Steps in multiple sclerosis (1995) (312)
Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. (2003) (310)
Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice (2010) (300)
CNS inflammation and neurodegeneration. (2017) (288)
Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin (1994) (287)
Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. (1996) (287)
Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen. (1990) (284)
Silencing MicroRNA-155 Ameliorates Experimental Autoimmune Encephalomyelitis (2011) (275)
Targeting miR‐155 restores abnormal microglia and attenuates disease in SOD1 mice (2015) (274)
IL-23 Is Increased in Dendritic Cells in Multiple Sclerosis and Down-Regulation of IL-23 by Antisense Oligos Increases Dendritic Cell IL-10 Production (2006) (274)
Role of the innate immune system in the pathogenesis of multiple sclerosis (2010) (273)
Disease steps in multiple sclerosis: a longitudinal study comparing Disease Steps and EDSS to evaluate disease progression (1999) (272)
MicroRNAs are universal regulators of differentiation, activation, and polarization of microglia and macrophages in normal and diseased CNS (2013) (267)
Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. II. Suppression of disease and in vitro immune responses is mediated by antigen-specific CD8+ T lymphocytes. (1989) (267)
Inflammation and therapeutic vaccination in CNS diseases (2002) (264)
IL-27 Is a Key Regulator of IL-10 and IL-17 Production by Human CD4+ T Cells1 (2009) (262)
Molecular basis of reovirus virulence: role of the S1 gene. (1977) (261)
MS: a CNS and systemic autoimmune disease. (1989) (258)
Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. (2004) (258)
Selective loss of the suppressor-inducer T-cell subset in progressive multiple sclerosis. Analysis with anti-2H4 monoclonal antibody. (1987) (254)
Epinephrine-induced changes in the distribution of lymphocyte subsets in peripheral blood of humans. (1983) (248)
Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis (2012) (246)
CD4+CD25− T Cells That Express Latency-Associated Peptide on the Surface Suppress CD4+CD45RBhigh-Induced Colitis by a TGF-β-Dependent Mechanism (2003) (245)
Oral Tolerance: Therapeutic Implications for Autoimmune Diseases (2006) (244)
Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+CD25−LAP+ T cells (2006) (244)
Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis (1993) (243)
IL‐4 is a differentiation factor for transforming growth factor‐β secreting Th3 cells and oral administration of IL‐4 enhances oral tolerance in experimental allergic encephalomyelitis (1998) (239)
Mucosal Administration of Heat Shock Protein-65 Decreases Atherosclerosis and Inflammation in Aortic Arch of Low-Density Lipoprotein Receptor-Deficient Mice (2002) (236)
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis (2008) (235)
Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39 (2019) (234)
mTOR cascade activation distinguishes tubers from focal cortical dysplasia (2004) (231)
Induction of oral tolerance to myelin basic protein in CD8-depleted mice: both CD4+ and CD8+ cells mediate active suppression. (1995) (229)
Regional magnetic resonance imaging lesion burden and cognitive function in multiple sclerosis: a longitudinal study. (2001) (228)
Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosis (2013) (226)
MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals (2003) (226)
Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent (2000) (226)
Absolute linkage of virulence and central nervous system cell tropism of reoviruses to viral hemagglutinin. (1980) (224)
Th3 Cells in Peripheral Tolerance. I. Induction of Foxp3-Positive Regulatory T Cells by Th3 Cells Derived from TGF-β T Cell-Transgenic Mice1 (2007) (222)
Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen. (1990) (220)
Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. (1998) (220)
Smoking and disease progression in multiple sclerosis. (2009) (217)
The mucosal milieu creates tolerogenic dendritic cells and TR1 and TH3 regulatory cells (2001) (217)
A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis (2008) (217)
Oral tolerance for the treatment of autoimmune diseases. (1997) (206)
Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. (2008) (204)
Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. (1997) (200)
The role of the CD58 locus in multiple sclerosis (2009) (200)
Immunology and immunotherapy of Alzheimer's disease (2006) (199)
Mesenteric lymph nodes are critical for the induction of high‐dose oral tolerance in the absence of Peyer's patches (2002) (197)
Endoscopic third ventriculostomy in patients with cerebrospinal fluid infection and/or hemorrhage. (2002) (196)
MicroRNA-21 promotes Th17 differentiation and mediates experimental autoimmune encephalomyelitis. (2015) (191)
Oral tolerance (2003) (191)
T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice (2010) (188)
Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E. (1995) (188)
Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE (2009) (187)
Gut-tropic T cells that express integrin α4β7 and CCR9 are required for induction of oral immune tolerance in mice. (2011) (178)
Epitopes of myelin basic protein that trigger TGF-beta release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression. (1993) (174)
Increased Osteopontin Expression in Dendritic Cells Amplifies IL-17 Production by CD4+ T Cells in Experimental Autoimmune Encephalomyelitis and in Multiple Sclerosis1 (2008) (173)
Double‐blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis (1989) (171)
Peripheral deletion of antigen-reactive T cells in oral tolerance (1995) (170)
Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. (2005) (169)
Oral tolerance to myelin basic protein induces regulatory TGF-beta-secreting T cells in Peyer's patches of SJL mice. (1994) (167)
Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. III. Synergistic effect of lipopolysaccharide. (1990) (167)
Novel therapeutic strategies for multiple sclerosis — a multifaceted adversary (2008) (167)
Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. (2004) (165)
Immune hyporesponsiveness to amyloid β-peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease (2001) (164)
The innate immune system in demyelinating disease (2012) (163)
Innate Immunity in Multiple Sclerosis: Myeloid Dendritic Cells in Secondary Progressive Multiple Sclerosis Are Activated and Drive a Proinflammatory Immune Response1 (2006) (162)
Immunologic Mechanisms and Therapy in Multiple Sclerosis (1995) (159)
Scara1 deficiency impairs clearance of soluble Amyloid-β by mononuclear phagocytes and accelerates Alzheimer’s-like disease progression (2013) (158)
Epilepsy Surgery in Young Children With Tuberous Sclerosis: Results of a Novel Approach (2006) (157)
In situ immune response in gut-associated lymphoid tissue (GALT) following oral antigen in TCR-transgenic mice. (1998) (156)
Induction of immunity and oral tolerance with polymorphic class II major histocompatibility complex allopeptides in the rat. (1992) (156)
Neutralization of reovirus: the gene responsible for the neutralization antigen (1977) (155)
Immunology and immunotherapy of Alzheimer's disease (2006) (155)
Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. (1997) (154)
Induction of oral tolerance to cellular immune responses in the absence of Peyer's patches (2001) (152)
Nasal Vaccination with Myelin Oligodendrocyte Glycoprotein Reduces Stroke Size by Inducing IL-10-Producing CD4+ T Cells1 (2003) (151)
Nasal Anti-CD3 Antibody Ameliorates Lupus by Inducing an IL-10-Secreting CD4+CD25−LAP+ Regulatory T Cell and Is Associated with Down-Regulation of IL-17+CD4+ICOS+CXCR5+ Follicular Helper T Cells1 (2008) (150)
Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects (2002) (149)
Latency-Associated Peptide Identifies a Novel CD4+CD25+ Regulatory T Cell Subset with TGFβ-Mediated Function and Enhanced Suppression of Experimental Autoimmune Encephalomyelitis1 (2008) (148)
TGF-β-Mediated Suppression by CD4+CD25+ T Cells Is Facilitated by CTLA-4 Signaling (2006) (148)
Induction of Th2 cell differentiation in the primary immune response: dendritic cells isolated from adherent cell culture treated with IL-10 prime naive CD4+ T cells to secrete IL-4. (1998) (146)
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring (2007) (146)
Oral tolerance, an active immunologic process mediated by multiple mechanisms. (2000) (146)
QTL influencing autoimmune diabetes and encephalomyelitis map to a 0.15-cM region containing Il2 (1999) (145)
Identification of the gene coding for the hemagglutinin of reovirus. (1978) (144)
Interaction of reovirus with cell surface receptors. I. Murine and human lymphocytes have a receptor for the hemagglutinin of reovirus type 3. (1980) (140)
Immunohistochemical staining of human brain with monoclonal antibodies that identify lymphocytes, monocytes, and the Ia antigen (1983) (136)
Neuroprotection by IL-10-producing MOG CD4+ T cells following ischemic stroke (2005) (136)
Genetic analysis of susceptibility to experimental autoimmune encephalomyelitis in a cross between SJL/J and B10.S mice. (1996) (133)
Aβ-induced meningoencephalitis is IFN-γ-dependent and is associated with T cell-dependent clearance of Aβ in a mouse model of Alzheimer's disease (2006) (132)
Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012. (2013) (132)
Antigen‐driven tissue‐specific suppression following oral tolerance: Orally administered myelin basic protein suppresses proteolipid protein‐induced experimental autoimmune encephalomyelitis in the SJL mouse (1994) (131)
A probiotic modulates the microbiome and immunity in multiple sclerosis (2018) (130)
Oligoclonal T lymphocytes in the cerebrospinal fluid of patients with multiple sclerosis [published erratum appears in J Exp Med 1988 Jul 1;168(1):459] (1988) (129)
What does the future hold for cell-based tolerogenic therapy? (2007) (129)
Oral, but not intravenous, alloantigen prevents accelerated allograft rejection by selective intragraft Th2 cell activation. (1993) (128)
IFN-Inducible Protein 10/CXC Chemokine Ligand 10-Independent Induction of Experimental Autoimmune Encephalomyelitis1 (2004) (128)
A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study. (2006) (128)
T-cell recognition of myelin basic protein. (1991) (128)
Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis. (1995) (126)
Deep Gray Matter Involvement on Brain MRI Scans Is Associated with Clinical Progression in Multiple Sclerosis (2009) (126)
Work productivity in relapsing multiple sclerosis: associations with disability, depression, fatigue, anxiety, cognition, and health-related quality of life. (2012) (126)
Immunotherapeutic Approaches to Alzheimer's Disease (2003) (125)
Cell-mediated immunity to myelin-associated glycoprotein, proteolipid protein, and myelin basic protein in multiple sclerosis (1986) (125)
AHR Activation Is Protective against Colitis Driven by T Cells in Humanized Mice. (2016) (125)
Quantitative analysis of MRI signal abnormalities of brain white matter with high reproducibility and accuracy (2002) (124)
Mechanisms of acquired thymic tolerance in experimental autoimmune encephalomyelitis: thymic dendritic-enriched cells induce specific peripheral T cell unresponsiveness in vivo (1995) (123)
Induction of medulloblastomas in mice by sonic hedgehog, independent of Gli1. (2002) (122)
The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research (2019) (120)
Oral tolerance induced by continuous feeding: enhanced up-regulation of transforming growth factor-beta/interleukin-10 and suppression of experimental autoimmune encephalomyelitis. (2003) (119)
Identification of a hemagglutinin-specific idiotype associated with reovirus recognition shared by lymphoid and neural cells (1982) (118)
Exploration of machine learning techniques in predicting multiple sclerosis disease course (2017) (117)
CTLA-4 is required for the induction of high dose oral tolerance. (1998) (117)
Myelin basic protein and proteolipid protein reactivity of brain- and cerebrospinal fluid-derived T cell clones in multiple sclerosis and postinfectious encephalomyelitis. (1987) (117)
The association between cognitive impairment and quality of life in patients with early multiple sclerosis (2010) (116)
Brain MRI Lesion Load at 1.5T and 3T versus Clinical Status in Multiple Sclerosis (2011) (114)
The Multiple Sclerosis Genomic Map: Role of peripheral immune cells and resident microglia in susceptibility (2017) (113)
Quantitative follow‐up of patients with multiple sclerosis using MRI: Technical aspects (1999) (113)
Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes. (2001) (111)
Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. (2000) (110)
Longitudinal MRI in multiple sclerosis (1994) (110)
Oral tolerance and TGF-beta-producing cells. (2006) (109)
Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. (2016) (108)
Oral administration of the immunodominant B-chain of insulin reduces diabetes in a co-transfer model of diabetes in the NOD mouse and is associated with a switch from Th1 to Th2 cytokines. (1997) (108)
Orally administered myelin basic protein in neonates primes for immune responses and enhances experimental autoimmune encephalomyelitis in adult animals (1994) (108)
Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. (2021) (108)
The role of mast cells in demyelination. 1. Myelin proteins are degraded by mast cell proteases and myelin basic protein and P2 can stimulate mast cell degranulation (1988) (108)
Quantitative follow‐up of patients with multiple sclerosis using MRI: Reproducibility (1999) (107)
T Cells in Multiple Sclerosis and Inflammatory Central Nervous System Diseases (1987) (107)
Inductive events in oral tolerance in the TCR transgenic adoptive transfer model. (1997) (106)
Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity. (2001) (106)
Inhibition of Autoimmune Diabetes by Oral Administration of Anti-CD3 Monoclonal Antibody (2007) (106)
B Cell-Deficient (μMT) Mice Have Alterations in the Cytokine Microenvironment of the Gut-Associated Lymphoid Tissue (GALT) and a Defect in the Low Dose Mechanism of Oral Tolerance1 (2001) (105)
Cutting Edge: Human Latency-Associated Peptide+ T Cells: A Novel Regulatory T Cell Subset (2010) (104)
Decreased severity of myelin oligodendrocyte glycoprotein peptide 33 – 35‐induced experimental autoimmune encephalomyelitis in mice with a disrupted TCR δ chain gene (1999) (102)
Regulatory Th2-type T cell lines against insulin and GAD peptides derived from orally- and nasally-treated NOD mice suppress diabetes. (1999) (100)
Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis (2018) (98)
Microbiota Signaling Pathways that Influence Neurologic Disease (2017) (98)
Extended major histocompatibility complex haplotypes in patients with multiple sclerosis (1989) (98)
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (2018) (98)
Immune response in subacute sclerosing panencephalitis: reduced antibody response to the matrix protein of measles virus. (1979) (97)
Tuberous sclerosis: A primary pathology of astrocytes? (2008) (97)
Repeat endoscopic third ventriculostomy: is it worth trying? (2001) (96)
Immunotherapy of multiple sclerosis (1988) (96)
Recovery from experimental allergic encephalomyelitis is TGF-beta dependent and associated with increases in CD4+LAP+ and CD4+CD25+ T cells. (2006) (95)
Identification of IgE-positive cells and mast cells in frozen sections of multiple sclerosis brains (1990) (94)
In Vivo Induction of Tr1 Cells via Mucosal Dendritic Cells and AHR Signaling (2011) (94)
Oral Administration of miR-30d from Feces of MS Patients Suppresses MS-like Symptoms in Mice by Expanding Akkermansia muciniphila. (2019) (94)
Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. (2004) (93)
Reciprocal expression of co‐stimulatory molecules, B7‐1 and B7‐2, on murine T cells following activation (1995) (93)
DOWN‐REGULATION OF THE IMMUNE RESPONSE TO HISTOCOMPATIBILITY ANTIGENS AND PREVENTION OF SENSITIZATION BY SKIN ALLOGRAFTS BY ORALLY ADMINISTERED ALLOANTIGEN1 (1992) (93)
IL-18 is linked to raised IFN-γ in multiple sclerosis and is induced by activated CD4+ T cells via CD40–CD40 ligand interactions (2002) (91)
Antigen reactive memory T cells are defined by Ta1. (1986) (90)
Neuroimmunology I: Immunoregulation in neurological disease (1982) (90)
Generation of cytolytic T lymphocytes after reovirus infection: role of S1 gene. (1979) (89)
Th3 Cells in Peripheral Tolerance. II. TGF-β-Transgenic Th3 Cells Rescue IL-2-Deficient Mice from Autoimmunity1 (2007) (89)
Long-term quality of life and neuropsychologic functioning for patients with CNS germ-cell tumors: from the First International CNS Germ-Cell Tumor Study. (2001) (87)
Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. Immunosuppressive effects and human anti-mouse responses. (1988) (87)
In vivo labeling of blood T cells: Rapid traffic into cerebrospinal fluid in multiple sclerosis (1987) (87)
Immunoregulatory T‐cells and lymphocytotoxic antibodies in active multiple sclerosis: Weekly analysis over a six‐month period (1983) (86)
Targeting monocyte recruitment in CNS autoimmune disease. (2002) (86)
The ICOS Molecule Plays a Crucial Role in the Development of Mucosal Tolerance1 (2005) (86)
Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. (2006) (86)
Developmental brain abnormalities in tuberous sclerosis complex: A comparative tissue analysis of cortical tubers and perituberal cortex (2014) (86)
Microglia inhibit photoreceptor cell death and regulate immune cell infiltration in response to retinal detachment (2018) (85)
IFN-γ Limits Th9-Mediated Autoimmune Inflammation through Dendritic Cell Modulation of IL-27 (2012) (84)
Pediatric Intramedullary Spinal Cord Tumors: Special Considerations (2000) (84)
Cutting Edge: Immature Human Dendritic Cells Express Latency-Associated Peptide and Inhibit T Cell Activation in a TGF-β-Dependent Manner1 (2007) (84)
Investigation of probiotics in multiple sclerosis (2018) (84)
Peripheral tolerance of Th2 lymphocytes induced by continuous feeding of ovalbumin. (1996) (83)
IL-12 Drives IFN-γ-Dependent Autoimmune Kidney Disease in MRL-Fas lpr Mice (1999) (83)
The 2H4 (CD45R) antigen is selectively decreased in multiple sclerosis lesions. (1988) (83)
Age dependent susceptibility to reovirus type 3 encephalitis: Role of viral and host factors (1983) (83)
Interaction of Viruses with Cell Surface Receptors (1982) (82)
PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells. (2004) (82)
Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: Increased interleukin‐4 production and associated eosinophilia (1997) (82)
Complications of fourth-ventricular shunts. (1995) (82)
Monoclonal gammopathy and neuropathy (1986) (82)
Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. (2008) (81)
Novel CD8+ Treg suppress EAE by TGF‐β‐ and IFN‐γ‐dependent mechanisms (2009) (81)
Depletion of TGF-β from fetal bovine serum. (2010) (81)
Multistage Epilepsy Surgery: Safety, Efficacy, and Utility of a Novel Approach in Pediatric Extratemporal Epilepsy (2005) (81)
Blood neurofilament light: a critical review of its application to neurologic disease (2020) (81)
Markers of cellular proliferation are expressed in cortical tubers (2003) (81)
Microglia-Mediated Nitric Oxide Cytotoxicity of T Cells Following Amyloid β-Peptide Presentation to Th1 Cells 1 (2003) (81)
The importance of cell‐mediated immunity in the course and severity of autoimmune anti‐glomerular basement membrane disease in mice (2003) (80)
Identification of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN-γ limits IL-17–mediated autoimmune inflammation (2010) (80)
Cognitive deterioration in patients with early multiple sclerosis: a 5-year study (2011) (80)
Nasal Vaccination with β-Amyloid Peptide for the Treatment of Alzheimer's Disease (2001) (80)
Dominant role of microglial and macrophage innate immune responses in human ischemic infarcts (2017) (79)
Surgical Outcome in Tuberous Sclerosis Complex: A Multicenter Survey (2007) (79)
IL-10-dependent Tr1 cells attenuate astrocyte activation and ameliorate chronic central nervous system inflammation (2016) (79)
3 T MRI relaxometry detects T2 prolongation in the cerebral normal-appearing white matter in multiple sclerosis (2009) (78)
The Relationship between Normal Cerebral Perfusion Patterns and White Matter Lesion Distribution in 1,249 Patients with Multiple Sclerosis (2012) (78)
Natural killer cell activity in multiple sclerosis. (1981) (78)
Adaptive Autoimmunity and Foxp3-Based Immunoregulation in Zebrafish (2010) (78)
Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage (2000) (78)
T-cell vaccination. (1988) (77)
Oral Administration of Myelin Induces Antigen‐specific TGF‐β1 Secreting T Cells in Patients with Multiple Sclerosis a (1997) (77)
Anti-immunoglobulin stimulation of murine lymphocytes. I. Age dependency of the proliferative response. (1976) (77)
Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician (2008) (76)
Modeling Disease Severity in Multiple Sclerosis Using Electronic Health Records (2013) (76)
Genetic susceptibility or resistance to autoimmune encephalomyelitis in MHC congenic mice is associated with differential production of pro- and anti-inflammatory cytokines. (1999) (76)
Extracellular RNAs: development as biomarkers of human disease (2015) (75)
Oral tolerance (2005) (75)
Transcriptional signature of human pro-inflammatory TH17 cells identifies reduced IL10 gene expression in multiple sclerosis (2017) (75)
Oral Administration of OKT3 Monoclonal Antibody to Human Subjects Induces a Dose-Dependent Immunologic Effect in T Cells and Dendritic Cells (2009) (74)
Demographic and clinical characteristics of malignant multiple sclerosis (2011) (74)
Immunologic responses of progressive multiple sclerosis patients treated with an anti‐T‐cell monoclonal antibody, anti‐T12 (1986) (74)
Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosis. (2016) (74)
Loss of functional suppression is linked to decreases in circulating suppressor inducer (CD4 + 2H4 +) T Cells in multiple sclerosis (1988) (74)
Consistent and Selective Expression of the Discoidin Domain Receptor-1 Tyrosine Kinase in Human Brain Tumors (2000) (73)
Induction of colitis in mice deficient of Peyer's patches and mesenteric lymph nodes is associated with increased disease severity and formation of colonic lymphoid patches. (2002) (73)
Severity of manifestations in tuberous sclerosis complex in relation to genotype (2014) (73)
An immunoregulatory and tissue-residency program modulated by c-MAF in human TH17 cells (2018) (73)
Acquired tolerance to experimental autoimmune encephalomyelitis by intrathymic injection of myelin basic protein or its major encephalitogenic peptide (1993) (73)
IL-4-Deficient and Transgenic Mice Demonstrated by Studies of IL-10- and Autoimmune Encephalomyelitis as IL-10 Is Critical in the Regulation of (1998) (72)
Current treatment of normal-pressure hydrocephalus: comparison of flow-regulated and differential-pressure shunt valves. (1995) (72)
Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells (2005) (71)
Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin antigens: IV. Suppression of chronic relapsing disease in the lewis rat and strain 13 guinea pig (1991) (71)
Hsp65-producing Lactococcus lactis prevents experimental autoimmune encephalomyelitis in mice by inducing CD4+LAP+ regulatory T cells. (2013) (70)
Cutting edge: homologous recombination of the MHC class I K region defines new MHC-linked diabetogenic susceptibility gene(s) in nonobese diabetic mice. (1999) (70)
Suppression of collagen-induced arthritis by oral or nasal administration of type II collagen. (1999) (69)
CTLA4Ig treatment in patients with multiple sclerosis (2008) (69)
Treatment of progressive multiple sclerosis with pulse cyclophosphamidel methylprednisolone: Response to therapy is linked to the duration of progressive disease (1999) (69)
Epilepsy Surgery in Tuberous Sclerosis: Multistage Procedures With Bilateral or Multilobar Foci (2002) (69)
Calorie restriction slows age-related microbiota changes in an Alzheimer’s disease model in female mice (2019) (68)
Suppression of antigen-induced arthritis in Lewis rats by oral administration of type II collagen. (1995) (68)
CSF cells in multiple sclerosis (1983) (67)
Plasmapheresis in multiple sclerosis (1980) (67)
Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. (2006) (67)
Resective Epilepsy Surgery for Tuberous Sclerosis in Children: Determining Predictors of Seizure Outcomes in a Multicenter Retrospective Cohort Study. (2015) (67)
Comparison of Frameless Stereotactic Systems: Accuracy, Precision, and Applications (2001) (67)
Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis (2018) (66)
Pro‐inflammatory activation of microglia in the brain of patients with sepsis (2018) (65)
Systematic evaluation of RNA quality, microarray data reliability and pathway analysis in fresh, fresh frozen and formalin-fixed paraffin-embedded tissue samples (2018) (65)
Oral delivery of group A streptococcal cell walls augments circulating TGF-beta and suppresses streptococcal cell wall arthritis. (1998) (65)
Evaluation of an Online Platform for Multiple Sclerosis Research: Patient Description, Validation of Severity Scale, and Exploration of BMI Effects on Disease Course (2013) (65)
Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. V. Hierarchy of suppression by myelin basic protein from different species (1992) (64)
Increased IL-23 secretion and altered chemokine production by dendritic cells upon CD46 activation in patients with multiple sclerosis (2008) (64)
Platelets Play Differential Role During the Initiation and Progression of Autoimmune Neuroinflammation. (2015) (64)
Identification of genetic loci associated with paralysis, inflammation and weight loss in mouse experimental autoimmune encephalomyelitis. (2001) (63)
Surgery for angiographically occult cerebral aneurysms. (1993) (63)
Electrocorticographic evidence of perituberal cortex epileptogenicity in tuberous sclerosis complex. (2012) (63)
TGF-β Induces Surface LAP Expression on Murine CD4 T Cells Independent of Foxp3 Induction (2010) (63)
Decrease of suppressor inducer (cd4+ 2h4+) t cells in multiple sclerosis cerebrospinal fluid (1989) (63)
Refractory epilepsy in tuberous sclerosis: Vagus nerve stimulation with or without subsequent resective surgery (2009) (62)
B7.2 (CD86) but not B7.1 (CD80) costimulation is required for the induction of low dose oral tolerance. (1999) (62)
Cutting Edge: Oral Type I IFN-τ Promotes a Th2 Bias and Enhances Suppression of Autoimmune Encephalomyelitis by Oral Glatiramer Acetate1 (2002) (62)
Immunologic tolerance after oral administration of reovirus: requirement for two viral gene products for tolerance induction. (1981) (62)
Common T‐cell receptor Vβ usage in oligoclonal T lymphocytes derived from cerebrospinal fluid and blood of patients with multiple sclerosis (1991) (62)
Current Issues in the Treatment of Human Diseases by Mucosal Tolerance (2004) (62)
Oral administration of insulin to neonates suppresses spontaneous and cyclophosphamide induced diabetes in the NOD mouse. (2001) (61)
Hyponatremia in the postoperative craniofacial pediatric patient population: a connection to cerebral salt wasting syndrome and management of the disorder. (2001) (61)
Different kinetic patterns of cytokine gene expression in vivo in orally tolerant mice (1994) (61)
Viral receptors on isolated murine and human ependymal cells. (1982) (61)
An RNA Profile Identifies Two Subsets of Multiple Sclerosis Patients Differing in Disease Activity (2012) (60)
Prevention of experimental allergic encephalomyelitis (EAE) in the SJL/J mouse by whole body ultraviolet irradiation. (1984) (60)
Impaired glutamate recycling and GluN2B‐mediated neuronal calcium overload in mice lacking TGF‐β1 in the CNS (2013) (60)
Delayed hypersensitivity in mice infected with reovirus. I. Identification of host and viral gene products responsible for the immune response. (1980) (60)
T cell vaccination in multiple sclerosis: a preliminary report. (1992) (59)
Oral tolerance reduces Th17 cells as well as the overall inflammation in the central nervous system of EAE mice (2010) (59)
Gut Microbiome in Progressive Multiple Sclerosis (2021) (59)
Temozolomide is Active in Childhood, Progressive, Unresectable, Low-Grade Gliomas (2003) (59)
Oral tolerance: a biologically relevant pathway to generate peripheral tolerance against external and self antigens. (1994) (58)
Social confrontation “Stress” in aggressive fish is associated with an endogenous opioid-mediated suppression of proliferative response to mitogens and nonspecific cytotoxicity (1989) (57)
IL-27 Imparts Immunoregulatory Function to Human NK Cell Subsets (2011) (56)
Infection of neuronal cell cultures with reovirus mimics in vitro patterns of neurotropism (1984) (56)
Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. (2008) (56)
Epitope spreading as an early pathogenic event in pediatric multiple sclerosis (2014) (56)
Interferon-β treatment alters peripheral blood monocytes chemokine production in MS patients (2002) (56)
In Vivo Administration of IL‐4 Induces TGF‐β‐producing Cells and Protects Animals from Experimental Autoimmune Encephalomyelitis (1996) (56)
Antigen-driven peripheral immune tolerance: suppression of experimental autoimmmune encephalomyelitis and collagen-induced arthritis by aerosol administration of myelin basic protein or type II collagen. (1996) (56)
Delayed Surgical Resection of Central Nervous System Germ Cell Tumors (2002) (55)
Childhood multiple sclerosis: Clinical features and demonstration of changes in T cell subsets with disease activity (1982) (55)
Intraocular Inflammatory Disease (Uveitis) and the Use of Oral Tolerance. (1996) (55)
Intrathecal baclofen therapy: complication avoidance and management (2011) (54)
Meeting report: discussions and preliminary findings on extracellular RNA measurement methods from laboratories in the NIH Extracellular RNA Communication Consortium (2015) (54)
Increased percentage of IL-12+ monocytes in the blood correlates with the presence of active MRI lesions in MS (2001) (54)
Lymphocytotoxic antibodies in multiple sclerosis. (1977) (54)
Failure of immunosuppression with a ten- to 14-day course of high-dose intravenous cyclophosphamide to alter the progression of amyotrophic lateral sclerosis. (1986) (54)
Surgical management of primary central nervous system germ cell tumors: proceedings from the Second International Symposium on Central Nervous System Germ Cell Tumors. (2010) (53)
Characterization of immunomodulatory properties and accessory cell function of small intestinal epithelial cells. (1990) (53)
Platelets Recognize Brain-Specific Glycolipid Structures, Respond to Neurovascular Damage and Promote Neuroinflammation (2013) (53)
Decreased autologous mixed lymphocyte reaction in multiple sclerosis (1985) (53)
Anti-immunoglobulin stimulation of murine lymphocytes. II. Identification of cell surface target molecules and requirements for cross-linkage. (1976) (53)
Epilepsy surgery and tuberous sclerosis complex: special considerations. (2008) (52)
Delayed hypersensitivity in mice infected with reovirus. II. Induction of tolerance and suppressor T cells to viral specific gene products. (1980) (52)
Intra-axial tumors of the cervicomedullary junction: surgical results and long-term outcome. (1997) (52)
Deficiency of thrombospondin-1 reduces Th17 differentiation and attenuates experimental autoimmune encephalomyelitis. (2009) (52)
Targeting latency-associated peptide promotes antitumor immunity (2017) (52)
Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity (2017) (52)
Oral tolerance with copolymer 1 for the treatment of multiple sclerosis. (1999) (51)
History and mechanisms of oral tolerance. (2017) (51)
COVID-19 in teriflunomide-treated patients with multiple sclerosis (2020) (51)
Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis (2014) (51)
IL-12 drives IFN-gamma-dependent autoimmune kidney disease in MRL-Fas(lpr) mice. (1999) (51)
Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein VI. Suppression of adoptively transferred disease and differential effects of oral vs. intravenous tolerization (1993) (51)
Mucosal Anti-CD3 Monoclonal Antibody Attenuates Collagen-Induced Arthritis That Is Associated with Induction of LAP+ Regulatory T Cells and Is Enhanced by Administration of an Emulsome-Based Th2-Skewing Adjuvant (2010) (50)
Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study (2018) (50)
The role of growth factor receptors in central nervous system development and neoplasia. (1995) (49)
Autoreactive T cells in multiple sclerosis. (1992) (49)
HLA-DR Alleles in Amyloid β-Peptide Autoimmunity: A Highly Immunogenic Role for the DRB1*1501 Allele1 (2009) (49)
Natural killing of measles-infected cells by human lymphocytes. (1979) (49)
Sigmoid diverticular perforation in neurosurgical patients receiving high-dose corticosteroids. (1993) (49)
In vitro induction of regulatory T cells by anti-CD3 antibody in humans. (2008) (48)
Predicting short-term disability in multiple sclerosis (2007) (48)
Phenotypic and functional analysis of T cells cloned directly from the blood and cerebrospinal fluid of patients with multiple sclerosis (1985) (48)
Surgery in the management of primary intracranial germ cell tumors (1999) (48)
Skull deformities. (2004) (47)
Identification of MS-specific serum miRNAs in an international multicenter study (2018) (47)
Tuberous Sclerosis and Multiple Tubers: Localizing the Epileptogenic Zone (2004) (47)
Anti-immunoglobulin stimulation of murine lymphocytes. V. Age-related decline in Fc receptor-mediated immunoregulation. (1978) (47)
Cytokine secretion of myelin basic protein reactive T cells in patients with multiple sclerosis (1998) (46)
Monoclonal antibody identification of a 100-kDa membrane protein in HeLa cells and human spinal cord involved in poliovirus attachment. (1988) (46)
Effect of vitamin D on MS activity by disease-modifying therapy class (2015) (46)
Cyclophosphamide and plasma exchange in multiple sclerosis (1991) (46)
A nasal proteosome adjuvant activates microglia and prevents amyloid deposition (2008) (46)
Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-γ production of CD8+ T cells in secondary progressive multiple sclerosis (2004) (46)
Dose‐dependent Activation and Deletion of Antigen‐specific T Cells following Oral Tolerance (1996) (46)
Acute microglia ablation induces neurodegeneration in the somatosensory system (2018) (45)
Seasonal variation of interferon‐γ production in progressive multiple sclerosis (1998) (45)
Induction of partial immune tolerance to factor VIII through prior mucosal exposure to the factor VIII C2 domain (2006) (45)
Germ cell tumors of the CNS in children: recent advances in therapy (1999) (45)
Altered blood T-cell subsets in patients with multiple sclerosis (1984) (45)
Epilepsy surgery in tuberous sclerosis complex: early predictive elements and outcome (2008) (45)
Rate of brain atrophy in benign vs early multiple sclerosis. (2009) (45)
Interaction of reovirus with cell surface receptors. II. Generation of suppressor T cells by the hemagglutinin of reovirus type 3. (1980) (44)
Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development (2014) (43)
Antineural antibodies in the serum of patients with amyotrophic lateral sclerosis (1987) (43)
Investigation of in vivo activated T cells in multiple sclerosis and inflammatory central nervous system diseases. (1985) (43)
Mechanisms of recovery from experimental autoimmune encephalomyelitis: T cell deletion and immune deviation in myelin basic protein T cell receptor transgenic mice (1998) (43)
A working protocol to be used as a guideline for trials in multiple sclerosis. (1983) (43)
Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis (2012) (42)
Microglia-Mediated Nitric Oxide Cytotoxicity of T Cells Following Amyloid β Peptide Presentation to Th1 Cells (2004) (42)
Adoptive transfer of murine chronic-relapsing autoimmune encephalomyelitis Analysis of basic protein-reactive cells in lymphoid organs and nervous system of donor and recipient animals (1987) (42)
Binding of 125I-labeled reovirus to cell surface receptors. (1984) (42)
Control of the gut microbiome by fecal microRNA (2016) (42)
Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. (2005) (41)
Treatment of experimental allergic neuritis with nedocromil sodium (1989) (41)
Regulation of autoimmune response. (1994) (41)
Genes and Environment in Multiple Sclerosis project: A platform to investigate multiple sclerosis risk (2016) (40)
A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. (2010) (40)
Role of Immunosuppressive Therapy for the Treatment of Multiple Sclerosis (2012) (40)
Activation of CD 25 CD 4 Regulatory T Cells by Oral Antigen Administration 1 (2001) (40)
Effect of Oral Beta Interferon on Subsequent Immune Responsiveness (1996) (40)
An argument for broad use of high efficacy treatments in early multiple sclerosis (2019) (40)
Tolerance and suppressor mechanisms in experimental autoimmune encephalomyelitis: implications for immunotherapy of human autoimmune diseases (1991) (39)
Aging correlates with reduction in regulatory-type cytokines and T cells in the gut mucosa. (2011) (39)
New immunosuppressive approaches: Oral administration of CD3-specific antibody to treat autoimmunity (2008) (39)
Interferon‐β inhibits toll‐like receptor 9 processing in multiple sclerosis (2010) (39)
The short isoform of the CEACAM1 receptor in intestinal T cells regulates mucosal immunity and homeostasis via Tfh cell induction. (2012) (39)
Medulla Oblongata Volume: A Biomarker of Spinal Cord Damage and Disability in Multiple Sclerosis (2008) (38)
Population structure and HLA DRB1*1501 in the response of subjects with multiple sclerosis to first-line treatments (2011) (38)
Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis (2016) (38)
Oral administration of schistosome egg antigens and insulin B-chain generates and enhances Th2-type responses in NOD mice. (1998) (38)
γδ T cells control humoral immune response by inducing T follicular helper cell differentiation (2018) (38)
Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease. (2001) (37)
Quality of life following epilepsy surgery for children with tuberous sclerosis complex (2011) (37)
Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. (2000) (37)
The Use of Intraoperative Autotransfusion during Cranial Vault Remodeling for Craniosynostosis (2002) (37)
Overexpression of TGF-β1 Gene Induces Cell Surface Localized Glucose-Regulated Protein 78-Associated Latency-Associated Peptide/TGF-β (2010) (37)
7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions (2019) (37)
Multiple sclerosis vs Lyme disease: A case presentation to a discussant and a review of the literature (1999) (35)
Nonapoptotic and Extracellular Activity of Granzyme B Mediates Resistance to Regulatory T Cell (Treg) Suppression by HLA-DR−CD25hiCD127lo Tregs in Multiple Sclerosis and in Response to IL-6 (2015) (35)
Schwannoma of the fourth ventricle presenting with hemifacial spasm (2005) (35)
An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy (2014) (34)
A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity (2015) (34)
Autoimmunity following viral infection: demonstration of monoclonal antibodies against normal tissue following infection of mice with reovirus and demonstration of shared antigenicity between virus and lymphocytes (1984) (34)
Epilepsy Surgery for Children With Tuberous Sclerosis Complex (2004) (34)
Time-series modeling of multiple sclerosis disease activity: A promising window on disease progression and repair potential? (2007) (34)
Nasal vaccination with troponin reduces troponin specific T-cell responses and improves heart function in myocardial ischemia-reperfusion injury. (2009) (33)
Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis (2017) (33)
Local epileptogenic networks in tuberous sclerosis complex: A case review (2007) (33)
Dynamic regulation of serum aryl hydrocarbon receptor agonists in MS (2017) (33)
A 21 Point Unifying Hypothesis on the Etiology and Treatment of Multiple Sclerosis (1998) (33)
Prolonged intrathecal baclofen withdrawal syndrome. Case report and discussion of current therapeutic management. (2005) (32)
T cell receptor (TCR) usage determines disease susceptibility in experimental autoimmune encephalomyelitis: studies with TCR V beta 8.2 transgenic mice (1994) (32)
Increased proliferative response of human peripheral blood lymphocytes to anti-immunoglobulin antibodies in elderly people. (1978) (32)
Lymphocytes in multiple sclerosis (1979) (32)
Detection of microRNAs in microglia by real-time PCR in normal CNS and during neuroinflammation. (2012) (32)
Kinin B1 receptor expression on multiple sclerosis mononuclear cells: correlation with magnetic resonance imaging T2-weighted lesion volume and clinical disability. (2005) (32)
Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis (2016) (32)
Power estimation for non-standardized multisite studies (2016) (31)
T cell responses to myelin basic protein in experimental autoimmune encephalomyelitis-resistant BALB/c mice (1993) (31)
Immunotherapy of cerebrovascular amyloidosis in a transgenic mouse model (2012) (31)
Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus (2013) (31)
Three‐year Open Protocol Continuation Study of Oral Tolerization with Myelin Antigens in Multiple Sclerosis and Design of a Phase III Pivotal Trial (1996) (31)
Oral salbutamol decreases IL-12 in patients with secondary progressive multiple sclerosis (2001) (31)
Growth Factor Receptor Tyrosine Kinases: Cell Adhesion Kinase Family Suggests a Novel Signaling Mechanism in Cancer (2000) (31)
Dual‐Sensitivity Multiple Sclerosis Lesion and CSF Segmentation for Multichannel 3T Brain MRI (2017) (31)
Smad7 Controls Immunoregulatory PDL2/1-PD1 Signaling in Intestinal Inflammation and Autoimmunity (2019) (31)
Increased Archaea Species and Changes with Therapy in Gut Microbiome of Multiple Sclerosis Subjects (S24.001) (2014) (30)
Role of Th1 and Th2 cells in neurologic disorders. (1996) (30)
The mechanism of nasal tolerance in lupus prone mice is T-cell anergy induced by immature B cells that lack B7 expression. (2006) (30)
MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis (2014) (30)
Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). (2002) (30)
Loss of functional suppression is linked to decreases in circulating suppressor-inducer (CD4+2H4+) T cells in multiple sclerosis (1987) (30)
Mechanisms of Oral Tolerance by MHC Peptides (1996) (30)
Evaluating more naturalistic outcome measures (2015) (30)
LYMPHOCYTOTOXIC ANTIBODIES IN FAMILY MEMBERS OF PATIENTS WITH MULTIPLE SCLEROSIS (1978) (30)
Oral tolerance to copolymer 1 in myelin basic protein (MBP) TCR transgenic mice: cross-reactivity with MBP-specific TCR and differential induction of anti-inflammatory cytokines. (2002) (30)
Effects of Immunomodulatory Substances on Phagocytosis of Aβ 1–42 by Human Microglia (2010) (29)
Induction of Immunological Tolerance by Oral Anti-CD3 (2011) (29)
Oral Tolerance: Physiologic Basis and Clinical Applications (2005) (29)
Central nervous system manifestations of tuberous sclerosis complex (2018) (29)
Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study (2009) (28)
Pulse cyclophosphamide plus methylprednisolone induces myelin-antigen-specific IL-4-secreting T cells in multiple sclerosis patients. (1998) (28)
Nonencephalitogenic CD4-CD8- V alpha 2V beta 8.2+ anti-myelin basic protein rat T lymphocytes inhibit disease induction. (1991) (28)
Treatment satisfaction in multiple sclerosis. (2014) (28)
Immunologic effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis (1991) (28)
Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation (2015) (28)
Improved relapse recovery in paediatric compared to adult multiple sclerosis. (2020) (28)
Type 1 human poliovirus binds to human synaptosomes (1987) (28)
CTLA4Ig treatment in patients with multiple sclerosis An open-label, phase 1 clinical trial (2008) (28)
Type-specific reovirus antiserum blocks the cytotoxic T-cell-target cell interaction: evidence for the association of the viral hemagglutinin of a nonenveloped virus with the cell surface (1981) (27)
Restoring immune tolerance in neuromyelitis optica (2016) (27)
A potential pathway of Th2 development during primary immune response. IL-10 pretreated dendritic cells can prime naive CD4+ T cells to secrete IL-4. (1997) (27)
Contrast-enhancing progressive multifocal leukoencephalopathy: radiological and pathological correlations: case report. (1996) (27)
Antigen‐Driven Peripheral Immune Tolerance (1991) (26)
Oral tolerance : mechanisms and applications (1996) (26)
Epileptogenic but MRI-normal perituberal tissue in Tuberous Sclerosis Complex contains tuber-specific abnormalities (2015) (26)
Identification and characterization of latency-associated peptide-expressing γδ T cells (2015) (26)
Activated Human CD4+CD45RO+ Memory T-Cells Indirectly Inhibit NLRP3 Inflammasome Activation through Downregulation of P2X7R Signalling (2012) (26)
Increased leptin and A-FABP levels in relapsing and progressive forms of MS (2013) (26)
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS (2016) (26)
The Use of Cyclophosphamide in the Treatment of Multiple Sclerosis a (1984) (26)
IL‐27 induction of IL‐21 from human CD8+ T cells induces granzyme B in an autocrine manner (2012) (26)
Multiple Epidural Hematomas and Hemodynamic Collapse Caused by a Subgaleal Drain and Suction-Induced Intracranial Hypotension: Case Report (2011) (25)
Potential of β2-Adrenoceptor Agonists as Add-On Therapy for Multiple Sclerosis (2002) (25)
Induction of Low Dose Oral Tolerance in Monocyte Chemoattractant Protein-1- and CCR2-Deficient Mice1 (2003) (25)
Pathogenic Transdifferentiation of Th17 Cells Contribute to Perpetuation of Rheumatoid Arthritis during Anti-TNF Treatment (2015) (25)
Environmental control of Th17 differentiation (2009) (25)
Antigen-driven peripheral immune tolerance. Suppression of organ-specific autoimmune diseases by oral administration of autoantigens. (1991) (25)
Membrane bound IL-15 is increased on CD14 monocytes in early stages of MS (2008) (25)
Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models (2015) (24)
Neuroimmunology II: Antigenic specificity of the nervous system (1982) (24)
The impact of a recent relapse on patient-reported outcomes in subjects with multiple sclerosis (2012) (24)
Temporal association of sNfL and gad‐enhancing lesions in multiple sclerosis (2020) (24)
Lymphocytapheresis in chronic progressive multiple sclerosis (1984) (23)
Systems biology approaches for the study of multiple sclerosis (2008) (23)
Developmental outcome of epilepsy surgery in tuberous sclerosis complex. (2005) (23)
Hung span method of scaphocephaly reconstruction in patients with elevated intracranial pressure. (2002) (23)
Induction of oral tolerization in CD86 deficient mice: a role for CD86 and B cells in the up-regulation of TGF-beta. (2006) (23)
A management strategy for intraventricular subependymal giant cell astrocytomas in tuberous sclerosis complex. (2014) (23)
Identification of Cytolytic CD161−CD56+ Regulatory CD8 T Cells in Human Peripheral Blood (2013) (22)
Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis (2020) (22)
Treatment of autoimmune diseases by oral tolerance to autoantigens. (1995) (22)
Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. (2019) (22)
Social support in multiple sclerosis: Associations with quality of life, depression, and anxiety. (2020) (22)
Safety of staged epilepsy surgery in children. (2014) (22)
An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2 (2014) (22)
Natalizumab: Immune effects and implications for therapy (2006) (21)
Antigen‐specific TGF‐β1 Secretion with Bovine Myelin Oral Tolerization in Multiple Sclerosis (1996) (21)
Oral tolerance: cytokine milieu in the gut and modulation of tolerance by cytokines. (1997) (21)
Restoring immune tolerance in neuromyelitis optica (2016) (21)
Checkpoint Receptor TIGIT Expressed on Tim-1+ B Cells Regulates Tissue Inflammation. (2020) (21)
Gray matter microglial activation in relapsing vs progressive MS: A [F-18]PBR06-PET study. (2019) (21)
Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course (2022) (21)
Serial blood T cell repertoire alterations in multiple sclerosis patients; correlation with clinical and MRI parameters (2006) (21)
Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis (2015) (21)
Estimating Time to Event From Longitudinal Categorical Data (2007) (21)
Lyt-1 cells mediate acute murine experimental allergic encephalomyelitis. (1984) (21)
Magnetic Resonance Imaging Surrogates of Multiple Sclerosis Pathology and Their Relationship to Central Nervous System Atrophy (2004) (21)
Results of an international questionnaire on immunosuppressive treatment of multiple sclerosis (2002) (21)
Intraventricular lesions in tuberous sclerosis complex: a possible association with the caudate nucleus. (2012) (21)
A Putative Alzheimer's Disease Risk Allele in PCK1 Influences Brain Atrophy in Multiple Sclerosis (2010) (20)
The ability of high field strength 7-T magnetic resonance imaging to reveal previously uncharacterized brain lesions in patients with tuberous sclerosis complex. (2013) (20)
Lymphocyte capping in muscular dystrophy (1979) (20)
CLA-supplemented diet accelerates experimental colorectal cancer by inducing TGF-β-producing macrophages and T cells (2018) (20)
Oral tolerance: mechanisms and applications. Introduction. (1996) (19)
HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study (2011) (19)
Immunosuppression with monoclonal antibodies in multiple sclerosis (1988) (19)
SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts (2018) (19)
Multiple Sclerosis. Diagnosis And Therapy (2012) (19)
History of fatigue in multiple sclerosis is associated with grey matter atrophy (2019) (19)
Brain MRI of nasal MOG therapeutic effect in relapsing-progressive EAE (2014) (19)
One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis (2011) (19)
Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study (2018) (19)
Immunosuppressive treatment in multiple sclerosis (2004) (19)
Identification of an IL-27/osteopontin Axis in Dendritic Cells and its Modulation by IFN-γ Limits IL-17 Mediated Autoimmune Inflammation (2010) (19)
Disruption of the ATP/adenosine balance in CD39−/− mice is associated with handling‐induced seizures (2017) (19)
In vivo anti-LAP mAb enhances IL-17/IFN-γ responses and abrogates anti-CD3-induced oral tolerance. (2014) (19)
Oral tolerance: elucidation of mechanisms and application to treatment of autoimmune diseases. (1997) (18)
An assessment of plasma exchange in progressive multiple sclerosis (1985) (18)
A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis (2017) (18)
A novel computer-assisted volumetric stereotactic approach for resecting tumors of the posterior parahippocampal gyrus. (1996) (18)
Seasonal variation of interferon-gamma production in progressive multiple sclerosis. (1998) (18)
Isolation and characterization of the class of human blood lymphocytes responsible for antibody-dependent cellular cytotoxicity. (1978) (18)
Microstructural fronto-striatal and temporo-insular alterations are associated with fatigue in patients with multiple sclerosis independent of white matter lesion load and depression (2020) (18)
Inflammatory cerebrospinal fluid t cells have activation requirements characteristic of cd4+cd45ra‐ t cells (1989) (18)
Pilot Study of Neurodevelopmental Impact of Early Epilepsy Surgery in Tuberous Sclerosis Complex. (2020) (18)
Defective regulation of IFNgamma and IL-12 by endogenous IL-10 in progressive MS. (2000) (18)
MicroRNA-21, T helper lineage and autoimmunity (2015) (18)
Lymphocyte capping in duchenne muscular dystrophy. (1979) (17)
Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis (2018) (17)
A method for evaluating treatment switching criteria in multiple sclerosis (2010) (17)
Immunosuppression and plasmapheresis in chronic progressive multiple sclerosis. Design of a clinical trial. (1983) (17)
The sex-specific interaction of the microbiome in neurodegenerative diseases (2019) (17)
Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis. (2019) (17)
Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count. (2018) (16)
Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study (2020) (16)
Therapy for multiple sclerosis. (1995) (16)
Monomethyl fumarate treatment impairs maturation of human myeloid dendritic cells and their ability to activate T cells (2019) (16)
Decreased CNS inflammation and absence of clinical exacerbation of disease after six months oral administration of bovine myelin in diseased SJL/J mice with chronic relapsing experimental autoimmune encephalomyelitis (1996) (16)
IL-6 Inhibits Upregulation of Membrane-Bound TGF-β 1 on CD4+ T Cells and Blocking IL-6 Enhances Oral Tolerance (2017) (16)
Extraventricular subependymal giant cell tumor in a child with tuberous sclerosis complex. (2009) (16)
Sigmoid Diverticular Perforation in Neurosurgical Patients Receiving High-Dose Corticosteroids (1993) (16)
Treatment of Multiple Sclerosis with Cyclophosphamide (1992) (16)
Time between expanded disability status scale (EDSS) scores. (2019) (16)
Induction of oral tolerance to the acetylcholine receptor for treatment of myasthenia gravis. (1999) (16)
Survivin controls biogenesis of microRNA in smokers: A link to pathogenesis of rheumatoid arthritis. (2017) (16)
T Cell Subsets in Patients with Multiple Sclerosis: An Overview a (1984) (16)
Murine CD4 T Cells Produce a New Form of TGF-β as Measured by a Newly Developed TGF-β Bioassay (2011) (16)
The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis. (2017) (16)
Retinal Pigment Epithelial Cells Induce foxp3+ Regulatory T Cells via Membrane-bound TGF-β (2010) (16)
Beneficial effect of orally administered myelin basic protein in EAE-susceptible Lewis rats in a model of acute CNS degeneration. (2003) (15)
Oral Tolerance to Insulin and the Insulin B‐Chain. (1996) (15)
Mucosal administration of CD3-specific monoclonal antibody inhibits diabetes in NOD mice and in a preclinical mouse model transgenic for the CD3 epsilon chain. (2017) (15)
Induction of low dose oral tolerance in IL-10 deficient mice with experimental autoimmune encephalomyelitis. (2004) (15)
Mucosal tolerance. (1999) (15)
Circulating CD4+CD8+ cells in myasthenia gravis: supplementary immunological parameter for long-term prognosis (1989) (15)
Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: A longitudinal study (2012) (15)
Redistribution of Lyt-bearing T cells in acute murine experimental allergic encephalomyelitis: selective migration of Lyt-1 cells to the central nervous system is associated with a transient depletion of Lyt-1 cells in peripheral blood. (1984) (15)
Decreased lymphocyte transformation to vaccinia virus in multiple sclerosis (1978) (15)
Interleukin-1 corrects the defective autologous mixed lymphocyte response in multiple sclerosis. (1991) (14)
Durable Efficacy of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Who Participated in the CARE-MS Studies: Three Year Follow-Up (S41.001) (2013) (14)
MRI phenotypes in MS (2019) (14)
Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis. (2017) (14)
18F-PBR06 Versus 11C-PBR28 PET for Assessing White Matter Translocator Protein Binding in Multiple Sclerosis (2018) (14)
Oral tolerance and the treatment of rheumatoid arthritis (2004) (14)
γδ T Cell–Secreted XCL1 Mediates Anti-CD3–Induced Oral Tolerance (2019) (14)
Stereotactic endoscopic resection and surgical management of a subependymal giant cell astrocytoma: case report. (2012) (14)
Aberrant expression of USF2 in refractory rheumatoid arthritis and its regulation of proinflammatory cytokines in Th17 cells (2020) (14)
Clinical practice of immunosuppressive treatments in multiple sclerosis: results of a second international questionnaire (2004) (14)
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (2020) (13)
Patient reported outcomes in benign multiple sclerosis (2011) (13)
Pilot Study of Oral Tolerance to Keyhole Limpet Hemocyanin in Humans. (1996) (13)
Neurology for the house officer (1983) (13)
The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis (2018) (13)
Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis (2019) (13)
Clonally restricted B cells in peripheral blood of multiple sclerosis patients: Kappa/lambda staining patterns (1982) (13)
Multiple sclerosis: what have we learned from magnetic resonance imaging studies? (1998) (13)
How does the immune system tolerate food? (2016) (13)
Patterning signals acting in the spinal cord override the organizing activity of the isthmus (1999) (13)
Intrathecal baclofen in X-linked adrenoleukodystrophy. (2001) (13)
Epilepsy surgery in tuberous sclerosis complex (TSC): emerging techniques and redefinition of treatment goals (2020) (13)
Editorial. Pediatric neurosurgery along with Children's Hospitals' innovations are rapid and uniform in response to the COVID-19 pandemic. (2020) (12)
Prenatal counseling for myelomeningocele in the era of fetal surgery: a shared decision-making approach. (2020) (12)
Oral treatment with foralumab, a fully human anti-CD3 monoclonal antibody, prevents skin xenograft rejection in humanized mice. (2017) (12)
Immunoregulation in multiple sclerosis. (1989) (12)
Induction of immunity and oral tolerance to alloantigen by polymorphic class II major histocompatibility complex allopeptides in the rat. (1993) (12)
LYMPHOCYTOTOXIC ANTIBODIES IN SUBACUTE SCLEROSING PANENCEPHALITIS AND AMYOTROPHIC LATERAL SCLEROSIS (1977) (12)
Effect of Natalizumab Treatment on Circulating Plasmacytoid Dendritic Cells: A Cross-Sectional Observational Study in Patients with Multiple Sclerosis (2014) (12)
Brain and cervical spinal cord atrophy in primary progressive multiple sclerosis: results from a placebo-controlled phase III trial (INFORMS) (2015) (12)
Leukopoietic Activity in Human Urine Following Operative Procedures 1 (1971) (12)
Medulloblastoma: mouse models and novel targeted therapies based on the Sonic hedgehog pathway. (2005) (12)
Antiidiotypic antibody to reovirus binds to neurons and protects from viral infection (1986) (12)
Anti-immunoglobulin stimulation of murine lymphocytes. IV. Re-expression and fate of cell surface receptors during stimulation. (1978) (12)
Manipulation of Th responses by oral tolerance. (1999) (12)
Interaction of reovirus with cell surface receptors. III. Reovirus type 3 induces capping of viral receptors on murine lymphocytes. (1981) (12)
Role of Mast Cells in Peripheral Nervous System Demyelination (1988) (12)
Proximal and distal effects of genetic susceptibility to multiple sclerosis on the T cell epigenome (2021) (12)
Hemispherectomy Outcome Prediction Scale: Development and validation of a seizure freedom prediction tool (2021) (11)
Unique findings of subependymal giant cell astrocytoma within cortical tubers in patients with tuberous sclerosis complex: a histopathological evaluation (2017) (11)
Latent-period stool proteomic assay of multiple sclerosis model indicates protective capacity of host-expressed protease inhibitors (2019) (11)
Interaction of reovirus with cell surface receptors. IV. The reovirus type 3 receptor is expressed predominantly on murine Lyt-2,3+ and human T8+ cells. (1984) (11)
Virus-binding receptors: Similarities to immune receptors as determined by anti-idiotypic antibodies (1982) (11)
Resection of Intraventricular Tumors in Children by Purely Endoscopic Means. (2016) (11)
The Effect of Fingolimod on Conversion of Acute Gadolinium‐Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis (2015) (11)
Demyelinating experimental allergic encephalomyelitis (EAE) in the rat: treatment with a monoclonal antibody against activated T cells (1988) (11)
A clonal model for human CD8+ regulatory T cells: Unrestricted contact‐dependent killing of activated CD4+ T cells (2012) (11)
Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis (2019) (11)
Biological activity of recombinant human myelin basic protein (1993) (11)
Secondary immune amplification following live poliovirus immunization in humans. (1987) (11)
Intrathecal Baclofen Therapy for the Treatment of Spasticity in Sjögren-Larsson Syndrome (2017) (11)
Multistage epilepsy surgery: safety, efficacy, and utility of a novel approach in pediatric extratemporal epilepsy. (2008) (11)
Cyclophosphamide therapy for MS. (2005) (11)
Double-blind study of true vs. sham plasmapheresis in patients being treated with immunosuppression for acute attacks of multiple sclerosis. (1990) (10)
Gray matter microglial activation in relapsing vs progressive MS (2019) (10)
Inhibit T Cell Activation in a TGF-andCells Express Latency-Associated Peptide Cutting Edge : Immature Human Dendritic (2007) (10)
Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis (2017) (10)
Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis (2021) (10)
Relationship of immunologic abnormalities and disease stage in multiple sclerosis: Implications for therapy (2007) (10)
Curing MS: How Science Is Solving the Mysteries of Multiple Sclerosis (2004) (10)
Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity (2020) (10)
Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMIT Study (2020) (10)
Pediatric neurosurgery along with children’s hospitals’ innovations are rapid and uniform in response to the COVID-19 pandemic (2020) (10)
Immunotherapy in autoimmune diseases. (1991) (10)
Tuberous sclerosis complex: molecular pathogenesis and animal models. (2006) (10)
Role of Endogenous Opioids in Modulating Some Immune Functions in Hybrid Tilapia (1989) (10)
PD-L1+ and XCR1+ dendritic cells are region-specific regulators of gut homeostasis (2021) (10)
Plasma exchange in acute multiple sclerosis. Design of a cooperative study. (1983) (10)
Extraoperative Functional Mapping and Staged Resection of Supratentorial Tumors near Eloquent Cortex in Children (2009) (10)
Epilepsy surgery in infants up to 3 months of age: Safety, feasibility, and outcomes: A multicenter, multinational study (2021) (10)
A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis (2017) (9)
Surface immunoglobulin and Fc receptors on murine B lymphocytes: loss of receptor interaction after cell activation. (1977) (9)
Cellular Components and Mechanisms of Oral Tolerance Induction. (2018) (9)
TSPO-PET Imaging to Assess Cerebral Microglial Activation in Multiple Sclerosis (2017) (9)
Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability (2021) (9)
Differentiation of experimental white matter lesions using multiparametric magnetic resonance measurements. (1991) (9)
Pediatric Craniomaxillofacial Oncologic Reconstruction. (2019) (9)
Generation of a monoclonal antibody (Epenl) which binds selectively to murine ependymal cells (1983) (9)
T‐cell subsets in human autoimmune diseases (1982) (9)
Alemtuzumab treatment has no adverse impact on sperm quality, quantity, or motility: A CARE-MS substudy (2013) (9)
Study Design and Baseline Characteristics of the INFORMS Study: Fingolimod in Patients with Primary Progressive Multiple Sclerosis (P07.116) (2013) (9)
Antigen-driven regulation of experimental autoimmune encephalomyelitis. (1998) (9)
Cop 1 therapy for multiple sclerosis. (1987) (9)
Rat Experimental Autoimmune Encephalomyelitis (1994) (9)
Cross-sectional study of smoking exposure: no differential effect on OCT metrics in a cohort of MS patients (2019) (9)
Antigen-Specific Immunosuppression: Oral Tolerance for the Treatment of Autoimmune Disease (1995) (9)
Material specificity of memory deficits in children with temporal tumors and seizures: A case series (2017) (9)
Immunosuppression for multiple sclerosis. (1983) (8)
Immunologic aspects of neurologic and neuromuscular diseases. (1997) (8)
A One-Two Punch in the Gut May Trigger Multiple Sclerosis. (2020) (8)
[Immunologic suppression of experimental autoimmune uveitis]. (1991) (8)
Invasive monitoring after resection of epileptogenic neocortical lesions in multistaged epilepsy surgery in children (2018) (8)
Anti‐CD4 and Anti‐CD2 Monoclonal Antibody Infusions in Subjects with Multiple Sclerosis Immunosuppressive Effects and Human Antimouse Responses (1988) (8)
Diagnostic and therapeutic trials in multiple sclerosis (1989) (8)
Restoring immune tolerance in neuromyelitis optica: Part I (2018) (8)
Serial analysis of peripheral blood T‐cell phenotypes and myelin basic protein reactivity in experimental allergic encephalomyelitis (1987) (8)
Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif(R) Efficacy in Multiple Sclerosis II (CARE-MS II): A Phase 3 Study in Relapsing-Remitting Multiple Sclerosis Patients Who Relapsed on Prior Therapy (S01.004) (2012) (8)
Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate (2018) (8)
Anti-immunoglobulin stimulation of murine lymphocytes. III. Enhancement of the development of responsive B cells by thymic deprivation. (1977) (7)
Kappa light chains in spinal fluid for diagnosing multiple sclerosis. (1994) (7)
Resection of a Pediatric Thalamic Juvenile Pilocytic Astrocytoma with Whole Brain Tractography (2017) (7)
Oral tolerance: an updated review. (2022) (7)
Oral laquinimod for treatment of relapsing-remitting multiple sclerosis (2008) (7)
Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis (2011) (7)
Increased IgG secretion by unstimulated mononuclear cells in active multiple sclerosis and functional assessment of the T8 subset. (1985) (7)
Oral tolerance: mobilizing the gut. (1995) (7)
Antigen-specific immunosuppression: oral tolerance for the treatment of autoimmune disease. (1995) (7)
Author Correction: Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39 (2019) (7)
Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis (2020) (7)
How does Epstein-Barr virus trigger MS? (2022) (7)
Intracranial microvascular free flaps. (2009) (7)
Immunosuppressive therapy for multiple sclerosis. (2005) (7)
The Management of Spontaneous Intracerebral Hemorrhage (1992) (7)
Coagulation abnormalities in children undergoing epilepsy surgery. (2011) (7)
Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis I (CARE-MS I): A Phase 3 Study in Relapsing-Remitting Treatment-Naïve Patients (S01.006) (2012) (7)
Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis (2022) (7)
Oral tolerance : new insights and prospects for clinical application (2004) (7)
Immunogenicity of Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients in the CARE-MS II Study (P07.101) (2013) (6)
T-cell response to orally administered antigens and its role in the treatment of autoimmune diseases. (1998) (6)
Understanding natural and pathological autoimmunity (2006) (6)
Th1 and Th2 cells in health and disease (1996) (6)
Oral immunization with allogeneic splenocytes inhibits development of accelerated but not acute rejection of cardiac grafts: analysis of intragraft effector mechanisms. (1992) (6)
Regional microglial activation in the substantia nigra is linked with fatigue in MS (2020) (6)
Studies of Myelin Breakdown in Vitro (1989) (6)
Cortical and Subcortical Dysmetabolism Are Dynamic Markers of Clinical Disability and Course in Anti-LGI1 Encephalitis (2022) (6)
Effect of Alemtuzumab vs. Rebif(R) on Brain MRI Measurements: Results of CARE-MS I, a Phase 3 Study (S11.006) (2012) (6)
Plasmapheresis, lymphocytapheresis, and immunosuppressive drug therapy in multiple sclerosis. (1982) (6)
The Potential of Restricted T Cell Recognition of Myelin Basic Protein Epitopes in the Therapy of Multiple Sclerosis (1991) (6)
Antigen-driven regulation of experimental autoimmune encephalomyelitis (1998) (6)
Mucosal tolerance therapy in humans: Past and future (2019) (6)
Methotrexate in the treatment of multiple sclerosis (1996) (6)
The fine line between autoimmune and allergic encephalomyelitis (2001) (6)
Immunotherapy in autoimmune diseases (1992) (6)
Using multiple imputation to efficiently correct cerebral MRI whole brain lesion and atrophy data in patients with multiple sclerosis (2015) (6)
Plasmapheresis in multiple sclerosis (1981) (6)
Serum neurofilament levels and patient‐reported outcomes in multiple sclerosis (2021) (6)
Dissection of multiple sclerosis genetics identifies B and CD4+ T cells as driver cell subsets (2021) (5)
Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study (2021) (5)
Treatment of EAE and MS Subjects with Probiotic VSL#3 (P5.320) (2016) (5)
Food allergies are associated with increased disease activity in multiple sclerosis (2018) (5)
Epilepsy outcome following resection of low-grade brain tumors in children. (2019) (5)
MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis (2021) (5)
Oral administration of IL-4 and IL-10 enhance the induction of low dose oral tolerance (1998) (5)
Immunohistochemical analysis of suppressor-inducer and helper-inducer T cells in multiple sclerosis brain tissue (1987) (5)
Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis (2018) (5)
Cyclophosphamide treatment normalizes the increased IL-12 production in patients with chronic progressive MS and induces a Th2 cytokine switch (1998) (5)
A pharmacogenetic study implicates NINJ2 in the response to Interferon-β in multiple sclerosis (2020) (5)
The microbiota restrains neurodegenerative microglia in a model of amyotrophic lateral sclerosis (2022) (5)
Short Report: A Pilot Study of a Group Positive Psychology Intervention for Patients with Multiple Sclerosis. (2017) (5)
Antigen-Specific Immunosuppression: Oral Tolerance for the Treatment of Autoimmune Disease (Part 1 of 2) (1994) (5)
Brain MR spectroscopic abnormalities in “MRI-negative” tuberous sclerosis complex patients (2013) (5)
Cerebellar Mutism Syndrome in Pediatric Neuro-oncology: A Multidisciplinary Perspective and Call for Research Priorities. (2022) (5)
Protein Degradome of Spinal Cord Injury: Biomarkers and Potential Therapeutic Targets (2020) (5)
Early predictors of clinical and MRI outcomes using LASSO in multiple sclerosis. (2022) (5)
Intramedullary spinal epidermoid presenting after thoracic meningocele repair: case report. (2015) (5)
Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes (2022) (5)
Adverse Event Profile of Alemtuzumab over Time in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P01.174) (2013) (5)
THE MOLECULAR BASIS OF REOVIRUS VIRULENCE (1980) (5)
Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study. (2020) (4)
microRNA-92a promotes CNS autoimmunity by modulating the regulatory and inflammatory T cell balance (2022) (4)
Immunologic mechanisms in chronic demyelinating diseases of the central and peripheral nervous system. (1990) (4)
Pilot study assessing a seven-day continuous intrathecal topotecan infusion for recurrent or progressive leptomeningeal metastatic cancer (2014) (4)
Loss of Functional Suppression Is Linked to Decreases in Circulating Suppressor‐Inducer (CD4+2H4+) T Cells in Multiple Sclerosis (1988) (4)
Alemtuzumab Reduces MS Disease Activity in Active Relapsing-Remitting Multiple Sclerosis Patients Who Had Disease Activity on Prior Therapy (P07.093) (2013) (4)
Longitudinal quantitative analysis of the tuber-to-brain proportion in patients with tuberous sclerosis. (2013) (4)
Review of Phase III Clinical Trials Outcomes in Patients with Secondary Progressive Multiple Sclerosis. (2021) (4)
Role of T cells in neuromyelitis optica (2012) (4)
Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS (2022) (4)
Visualizing Lymph Node Structure and Cellular Localization using Ex-Vivo Confocal Microscopy. (2019) (4)
Targeting miR-155 restores dysfunctional microglia and ameliorates disease in the SOD1 model of ALS. (2015) (4)
Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis (2021) (4)
Oral Administration of Myelin Induces Antigen‐specific TGF‐β1‐secreting T Cells in Multiple Sclerosis Patients a (1997) (4)
'Lupus-prone' mice are susceptible to organ-specific autoimmune disease, experimental allergic encephalomyelitis. (1994) (4)
[The role of endogenous opioids in modulation of immunosuppression in fish]. (1992) (4)
Stroke Size by Inducing IL-10-Producing Oligodendrocyte Glycoprotein Reduces Nasal Vaccination with Myelin (2003) (4)
Regulating rejection with cell therapy (2008) (4)
Pediatric neurology for the house officer (1977) (4)
Serum antibodies to phosphatidylcholine in MS (2020) (4)
Glioma-like proliferation within tissues excised as tubers in patients with tuberous sclerosis complex (2008) (4)
Patient-reported outcomes associated with transition to secondary progressive multiple sclerosis (2021) (4)
CRANIOPHARYNGIOMAS. AUTHOR'S REPLY (1996) (4)
Experimental Approaches to Specific Immunotherapy in Multiple Sclerosis (1992) (3)
Antigen-specific therapies for the treatment of autoimmune diseases (2004) (3)
REMOVED: Targeting miR-155 restores dysfunctional microglia and ameliorates disease in the SOD1 model of ALS (2015) (3)
[F-18]PBR06 PET to assess TSPO binding and its association with brain atrophy and disability in multiple sclerosis (P3.386) (2018) (3)
Pediatric Language Mapping: Sensitivity of Neurostimulation and Wada Testing in Epilepsy Surgery: 880 (2006) (3)
Relapse Outcomes with Alemtuzumab vs IFNB-1a in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P07.098) (2013) (3)
The microbiome requires a genetically susceptible host to induce central nervous system autoimmunity (2020) (3)
Impact of genetic susceptibility to multiple sclerosis on the T cell epigenome: proximal and distal effects (2020) (3)
Induction of Medulloblastomas in Mice by Sonic Hedgehog , Independent of Gli 1 1 , 2 (2002) (3)
Focal Resection of Leptomeningeal Angioma in a Rare Case of Sturge-Weber Syndrome without Facial Nevus (2014) (3)
Comparison of health-related quality of life across treatment groups in individuals with multiple sclerosis. (2020) (3)
Chapter 39 – Oral Tolerance: Immunologic Mechanisms and Treatment of Autoimmune Diseases (1996) (3)
C 49 The treatment of the ocular complications of Behçet's disease with oral tolerizating using ocular antigens (1993) (3)
Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies. (1987) (3)
Seizures following surgery for supratentorial extratemporal low-grade tumors in children: a multicenter retrospective study. (2020) (3)
The role of T cell reactivity to A-beta amyloid peptide in the pathogenic processes associated with Alzheimer's disease (2000) (3)
Incidence of Autoimmunity in a Phase 3 Trial: Comparison of Alemtuzumab and Rebif(R) in Multiple Sclerosis I (CARE-MS I) (S41.006) (2012) (3)
Treatment of autoimmune diseases by oral tolerance to autoantigens. (1993) (3)
B4GALT6 regulates astrocyte activation during CNS inflammation (INM8P.360) (2015) (3)
Pathogenesis and treatment of central nervous system demyelinating disease. (1998) (3)
Comparison of the real‐world effectiveness of vertical versus lateral functional hemispherotomy techniques for pediatric drug‐resistant epilepsy: A post hoc analysis of the HOPS study (2021) (3)
Epilepsy in TSC (2010) (3)
Provider views on perioperative steroid use for patients with newly diagnosed pediatric brain tumors (2020) (3)
Epilepsy surgery in Panama: Establishment of a successful hybrid program as a model for small middle‐income countries (2018) (3)
Clonally Focused Public and Private T Cells in Resected Brain Tissue From Surgeries to Treat Children With Intractable Seizures (2021) (3)
Role of Cytokines in Multiple Sclerosis and in Mucosal Tolerance (2002) (3)
OR.103. Immature Human Dendritic Cells Express Latency-Associated Peptide (LAP) and Inhibit T-Cell Activation in a Tgf-β Dependent Fashion (2006) (2)
Regulation of splenic monocyte homeostasis and function by gut microbial products (2021) (2)
Abstracts from the ASENT 2010 annual meeting March 4–6, 2010 (2010) (2)
Technological advances in pediatric epilepsy surgery: implications for tuberous sclerosis complex (2017) (2)
Validation of Two Kinetic Assays for the Quantification of Endotoxin in Human Serum (2021) (2)
Sequestration of virus-specific T cells in the cerebrospinal fluid of a patient with varicella zoster viral meningoencephalitis (1989) (2)
Cyclophosphamide and MS‐RRR (1994) (2)
Pesacral mengocele associated with hereditary sacral agenesis and treated surgically: Evaluation in three members of the same family : Case report. Commentary (2005) (2)
Temporal trends of multiple sclerosis disease activity: Electronic health records indicators. (2021) (2)
A comprehensive evaluation of serum microRNAs as potential biomarkers in multiple sclerosis (P1.390) (2016) (2)
Effects of Red Meat Diet Restriction on Multiple Sclerosis Severity (P1.404) (2016) (2)
Inducing tolerance one antigen at a time (2016) (2)
Book Review Multiple Sclerosis: The History of a Disease By T. Jock Murray. 580 pp., illustrated. New York, Demos, 2005. $29.95. 1-888799-80-3 (2005) (2)
Silencing MicroRNA-155 Ameliorates (2011) (2)
Prevention of autoimmunity (1999) (2)
Circulating microRNAs as Biomarkers for Disease Staging in MS (S11.005) (2013) (2)
Anti-CD4 and anti-CD2 monoclonal antibodies infusions in multiple sclerosis: Immunosuppressive effects and human anti-mouse responses (1987) (2)
The development of antigen specific therapies for autoimmune diseases; investigations in multiple sclerosis as a paradigm for rheumatoid arthritis. (1993) (2)
Infections in Phase 3 Study: Comparison of Alemtuzumab and Rebif(R) Efficacy in Multiple Sclerosis I (CARE-MS I) (S41.007) (2012) (2)
Mechanism of Viral Injury to the Nervous System (1982) (2)
Mechanisms of Oral Tolerance to Soluble Protein Antigens (2015) (2)
Publisher Correction: An immunoregulatory and tissue-residency program modulated by c-MAF in human TH17 cells (2018) (2)
Antigen-specific therapies for the treatment of autoimmune diseases. (1995) (2)
Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis (2022) (2)
Early Predictors of Clinical and MRI Outcomes Using Least Absolute Shrinkage and Selection Operator (LASSO) in Multiple Sclerosis (2022) (2)
Relapse Outcomes with Alemtuzumab vs. Rebif® in Treatment-Naïve Relapsing-Remitting Multiple Sclerosis (CARE-MS I): Secondary and Tertiary Endpoints (PD5.004) (2012) (2)
CHAPTER 46 – Multiple Sclerosis (2006) (2)
Interferon tau induction of TH2 cytokines and synergy with oral MBP for treatment of experimental allergic encephalomyelitis (1998) (2)
Retracted Tuberous sclerosis complex: molecular pathogenesis and animal models (2006) (2)
Efficacy of Alemtuzumab vs IFNB-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II): Subgroup Analysis by Previous Disease Modifying Therapy (DMT) Use (P07.111) (2013) (2)
THE ROLE OF THE REOVIRUS HEMAGGLUTININ IN VIRAL VIRULENCE * (1980) (2)
Effect of Vitamin D level in the gut microbiome of MS patients (P2.206) (2015) (2)
ControlofT reg andT H 17celldifferentiation by the aryl hydrocarbon receptor (2008) (2)
Myeloid cell subsets that express latency-associated peptide promote cancer growth by modulating T cells (2021) (2)
Microglial Biology and Physiology (2017) (2)
Nasal Vaccination with Troponin Reduces Myocardial Ischemia-Reperfusion Injury By Inducing Il-10 Secreting Cd4+ T-Cells (2006) (2)
Local and Systemic Immune Responsees in SJL/J Mice during prolonged Oral Myelin Basic Protein Administration (1996) (1)
Fourth meeting of the European Neurological Society 25–29 June 1994 Barcelona, Spain (1994) (1)
Clinical Predictors for Fingolimod (Gilenya) Treatment Response in Multiple Sclerosis Patients (P7.226) (2014) (1)
IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. (2006) (1)
Suppression ofdiabetes innonobese diabetic micebyoral administration ofporcine insulin (diabetes/tolerance/autolmmunity/lmmunotherapy/insulin) (1991) (1)
Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes. (2023) (1)
Development of simple trial protocols. (1983) (1)
Insights into multiple sclerosis provided by non-coding RNAs: meeting summary from the symposium ‘Non-coding RNAs in autoimmune disorders of the central nervous system’ on 5 April 2013 in Warsaw, Poland (2014) (1)
97 : Silencing MicroRNA-21 ameliorates Th17 mediated autoimmune inflammation (2013) (1)
Immunoregulatory abnormalities induced by experimental reovirus infection: functional alterations in T-cell subpopulations. (1987) (1)
Myelin proteolipid protein specific TH2 clones suppress autoimmune encephalomyelitis (1994) (1)
Cerebral leptomeningeal enhancement is common and associated with cortical and thalamic lesions in relapsing-remitting multiple sclerosis: A 7T MRI study (S31.002) (2019) (1)
Genomic Evaluation of Multiple Sclerosis (2010) (1)
Corrigendum: Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE (2010) (1)
Brain Volume as a Predictor of Disability in Primary Progressive Multiple Sclerosis: Evidence from the INFORMS Trial (S51.007) (2016) (1)
Human LAP+ T Cells: A Novel Regulatory T Cell Subset (2010) (1)
Quantification of callosal widths using Conformal Mapping : Application to Multiple Sclerosis (2008) (1)
Increasing Efficiency of Intracranial Cavity Determination from High-Resolution 3 Tesla(T) MRI Scans of the Brain (P06.121) (2013) (1)
Quantitative MRI Phenotypes in Longitudinal Population of MS Patients. (2014) (1)
Oligoclonal T Lymphocytes in the Cerebrospinal Fluid of Patients with Chronic Progressive Multiple Sclerosis (1987) (1)
Comparison of Demographic and Disease Characteristics in Patients with Multiple Sclerosis at an MS Clinic and on an Online Research Forum (P01.145) (2012) (1)
Oral tolerance to glatiramer acetate (Copl, Copaxone) in MBPT cell receptor transgenic mice (1998) (1)
Future Therapeutic Approaches (2012) (1)
Nasal administration of anti-CD3 mAb (Foralumab) downregulates NKG7 and increases TGFB1 and GIMAP7 expression in T cells in subjects with COVID-19. (2023) (1)
Hemispheric Surgery Outcome Prediction Scale: Development and Validation of a Seizure Freedom Prediction Tool (2020) (1)
Multiple Sclerosis in the Elderly (2010) (1)
Induction ofanergy oractive suppression following oraltolerance isdetermined byantigen dosage (1994) (1)
Viral interactions with receptors in the central nervous system and on lymphocytes. (1983) (1)
Obesity is associated with the Optic Neuritis severity in Male patients with Multiple Sclerosis. (2021) (1)
Dissection of multiple sclerosis genetics identifies B and CD4+ T cells as driver cell subsets (2022) (1)
Author Correction: Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study (2020) (1)
Use of cyclophosphamide and other immunosuppressants to treat multiple sclerosis (2007) (1)
Correction: Platelets Recognize Brain-Specific Glycolipid Structures, Respond to Neurovascular Damage and Promote Neuroinflammation (2014) (1)
CD8+ T cells in neurodegeneration: friend or foe? (2022) (1)
Suppression of Experimental Autoimmune Encephalomyelitis with Nanoparticles Carrying a Central Nervous System Antigen and a Non-Toxic Aryl Hydrocarbon Receptor Ligand (SC01.004) (2012) (1)
Inhibition of T cell responses by activated CD8+ T cells is mediated by IFN-γ and is defective in chronic progressive multiple sclerosis (1994) (1)
TRANSIENT SYRINGOMYELIA LEADING TO ACUTE NEUROLOGICAL DETERIORATION AFTER REPAIR OF A LIPOMYELOMENINGOCELE: CASE REPORT (2007) (1)
Dimethyl fumarate versus interferon for treatment of relapsing-remitting multiple Sclerosis (P6.381) (2017) (1)
Cumulative Experience with High‐Dose Intravenous Cyclophosphamide and ACTH Therapy in Chronic Progressive Multiple Sclerosis (1988) (1)
Myelin basic protein (MBP)-specific TGFβ-secreting CD4+ T-cell clones derived from orally tolerized animals suppress experimental autoimmune encephalomyelitis (1994) (1)
REMOVED: Identification of a unique molecular and functional microglia signature in health and disease (2015) (1)
Outcomes in neurological and neurosurgical disorders: Mechanical disorders of the spine (1998) (1)
Abstracts from the ASENT 2008 Annual Meeting March 6–8, 2008 (2008) (1)
Evaluation of ventriculoperitoneal shunt emergencies. (2009) (1)
An At-home Positive Psychology Intervention for Individuals with Multiple Sclerosis: A Phase 1 Randomized Controlled Trial. (2020) (1)
Activated Human CD 4 + CD 45 RO + Memory T-Cells Indirectly Inhibit NLRP 3 Inflammasome Activation through Downregulation of P 2 X 7 R Signalling (2012) (1)
The role of mast cells in PNS demyelination (1987) (1)
OR.46. Control of Treg and Th17 Differentiation by AHR (2008) (1)
Oligocllonal T lymphocytes in the cerebrospinal fluid (CSF) of patients with chronic progressive multiple sclerosis (1987) (1)
Beta-Catenin Mutation with Complex Chromosomal Changes in Desmoid Tumor of the Scalp: A Case Report (2019) (1)
Plasma exchange for MS (1990) (1)
Specific Serum Antibody Patterns Detected with Antigen Arrays Are Associated to the Development of MS in Pediatric Patients (S60.006) (2012) (1)
Introduction (1996) (1)
Widespread Glial Activation in Primary Progressive Multiple Sclerosis Revealed by 18F-PBR06 PET (2020) (1)
Corrigendum: Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study (2022) (1)
IL-6R signaling inhibits generation of Th3 cells and is a promising therapeutic target for enhancing oral tolerance induction (2016) (1)
The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis (2021) (1)
Immune regulatory effects of FTY720 on Dendritic cells (P1.142) (2015) (1)
Immunohistochemical Analysis of Suppressor‐Inducer and Helper‐Inducer T Cells in Multiple Sclerosis Brain Tissue (1988) (1)
Anti-Immunoglobulin Stimulation of Murine Lymphocytes (1976) (1)
Correlation of Magnetic Resonance Imaging With Immune and Clinical Measures in 45 MS Patients Receiving 20 to 24 MRI Scans Each Over a 1 ‐Year Period (1995) (1)
Immune System, Innate; Overview (2014) (1)
The Central and Peripheral Nervous System Immunological Compartments in Health and Disease (2019) (1)
Identification of a unique molecular and functional microglia signature in health and disease. (2015) (1)
Immunoregulation in multiple sclerosis. (1983) (1)
Encephalomyelitis Experimental Autoimmune Ligand 10-Independent Induction of IFN-Inducible Protein 10 / CXC Chemokine and (2003) (0)
MicroRNA-92a controls the balance between inflammatory and regulatory T cells in CNS autoimmunity (2020) (0)
Human T Cells Suppress NLRP3 Inflammasome Activation of Monocytes in the Presence of Interferon-beta (2010) (0)
measures 1-year smartphone study in multiple sclerosis (2015) (0)
Immune regulatory effects of FTY720 on human T cells (P1.143) (2015) (0)
Factor Affecting Recovery from Acute Optic Neuritis in Multiple Sclerosis Patients (P2.260) (2014) (0)
An immunoregulatory and tissue-residency program modulated by c-MAF in human TH17 cells (2018) (0)
Targeting Epstein-Barr virus to treat MS. (2022) (0)
Lymphocyte Dynamics During and After Fingolimod Therapy: Long-Term Data from the INFORMS Trial (P5.294) (2016) (0)
Pediatric neurosurgery at Texas Children's Hospital: the legacy of Dr. William R. Cheek. (2021) (0)
Immunotherapeutic Approaches for Multiple Sclerosis* (2019) (0)
In Vivo Assessment of Retinal Neuronal Layers in Multiple Sclerosis Patients (P2.259) (2014) (0)
Subependymal Giant Cell Astrocytoma (2015) (0)
Identification of a Unique miRNA Signature in CD14+/CD16- Blood-Monocytes in ALS Subjects Identical to That Observed in SOD Mice (P05.167) (2012) (0)
Contents, Vol. 22, 1995 (1985) (0)
Defective Induction of Tolerogenic Myeloid DCs by IL-27 in Relapsing MS (P2.104) (2016) (0)
Publisher Correction: An immunoregulatory and tissue-residency program modulated by c-MAF in human TH17 cells (2018) (0)
Clinical and Immunologic Characterization of MRI-Defined Phenotypes in Multiple Sclerosis: a Longitudinal Study (P2.371) (2018) (0)
Abstracts from ASENT 2004 Annual Meeting March 11–13, 2004 (2004) (0)
the Development of Mucosal Tolerance The ICOS Molecule Plays a Crucial Role in (2005) (0)
Reply (2011) (0)
Identi fi cation of an IL-27 / osteopontin axis in dendritic cells and its modulation by IFN-γ limits IL-17 – mediated autoimmune in fl ammation (2010) (0)
Anti-immunoglobulin stimulation of murine lymphocytes. Abstr. (1976) (0)
Antigen presentation by astrocytes--a commentary. (1986) (0)
Abstract A85: The role of LAP positive immune cells in cancer (2020) (0)
Interaction (1988) (0)
Multiple Sclerosis Autoimmune Encephalomyelitis and in T Cells in Experimental + by CD4 Dendritic Cells Amplifies IL-17 Production Increased Osteopontin Expression in (2008) (0)
Redo Endoscopic Third Ventriculostomy: Worth Trying? (1999) (0)
A longitudinal study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis. (P6.170) (2015) (0)
Does Alcohol and Red Wine Consumption Play a Role in Multiple Sclerosis Disease Course? (P2.213) (2015) (0)
2 Mechanisms of oral tolerance and treatment of animal and human autoimmune diseases (1994) (0)
The Children's Ward (1980) (0)
Younger age at multiple sclerosis onset is associated with worse outcomes at age 50 (2022) (0)
Clinical inflammatory activity associated with response to second-line treatments in multiple sclerosis (2013) (0)
Trial design and baseline data of the INFORMS (fingolimod in patients with primary progressive multiple sclerosis) study (2012) (0)
Hormonal Associations in the Early Disease Course in Men with Relapsing Remitting Multiple Sclerosis (P02.128) (2013) (0)
[The trimolecular complex as a target for specific immunotherapy in experimental autoimmune encephalomyelitis--applications for multiple sclerosis and other human autoimmune disease]. (1992) (0)
Suppression of autoimmune diseases by antigenic in wartestellung (1993) (0)
Sa.26. Modification of Dendritic Cells by Th3 Cells Derived from Tgf-Beta Transgenic Mice (2006) (0)
Lack of mucosa associated lymphatic tissue deteriorates acute and chronic intestinal inflammation in mice (2001) (0)
Requirement for antigen processing and influence of invariant chain and H-2M deficiencies on T-Cell activation in autoimmune encephalomyelitis (2001) (0)
Regulatory T cells (PP-045) (2010) (0)
Treatment of Alzheimer’s disease by modulation of microglial neuroinflammation by nasal anti‐CD3 mAb (2022) (0)
Psychiatry at UCSF. (1994) (0)
Lymphocytotix antibodies in subacute sclerosing panencephalitis and amyotrophic lateral sclerosis. (1977) (0)
MicroRNA control of inflammatory and regulatory T cells in CNS autoimmunity (2022) (0)
Discontinuation of Disease-Modifying Therapy for Patient with Relapsing-Remitting Multiple Sclerosis (2019) (0)
Role of Immunosuppressive Therapy for the Treatment of Multiple Sclerosis (2012) (0)
OR.104. Induction of Regulatory T Cells by Mucosal Administration of Aryl Hydrocarbon Receptor Ligands and Anti-CD3 Monoclonal Antibody in Animals and Humans (2009) (0)
Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine (2023) (0)
Author Correction: Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39 (2019) (0)
T-cell proliferation to insulin or GAD and susceptibility to EAE induction in NOD and III mice, carrying the same g7 MHC, is linked to differential cytokine production (2009) (0)
Microglial Activation in the Deep Grey Matter is Associated with Regional Atrophy and Physical Disability in Multiple Sclerosis (S12.003) (2019) (0)
Oral tolerance reduces il-17 secretion both in the periphery as well as in the central nervous system of eae mice (2010) (0)
Reply (1990) (0)
Improved Specificity of Multiple Sclerosis Lesion Segmentation from Dual-Sensitivity MRI Morphometry (P6.116) (2015) (0)
Allergies Are Associated with Increased Disease Activity in Multiple Sclerosis (P2.187) (2016) (0)
Sa.121. Induction of CD4+-CD25-Lap+- Regulatory T-Cells By Dendritic Cells from Gut Associated Lymphoid Tissue (2006) (0)
Brain and Spinal Cord MRI Findings in Primary Progressive vs. Relapsing-Remitting Multiple Sclerosis (P4.170) (2016) (0)
Multiple Sclerosis: The Next 20 Years (2011) (0)
Social confrontation in aggressive fish tilapia is associated with an endogenous opioid system mediated suppression of immunological functions (1988) (0)
Influence of invariant chain and H-2M deficiencies in antigen processing and T cell activation in autoimmune encephalomyelitis. (2000) (0)
Faculty Opinions recommendation of Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. (2011) (0)
Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8+ T cell function and induces a regulatory response in T cells in human subjects (2022) (0)
The role of the CD[subscript 5]8 locus in multiple sclerosis (2009) (0)
Th2 and Th3 (TGF-beta) responses are associated with regulation of CNS autoimmunity in EAE and therapy of multiple sclerosis (1998) (0)
CD8+ T cells in neurodegeneration: friend or foe? (2022) (0)
Large Scale Immunoprofiling Uncovers Population Structure in Untreated MS Subjects and Highlights the Role of NK Cells (2007) (0)
Validation of Routine High-Resolution 3T MRI Morphometry in Multiple Sclerosis (P6.164) (2015) (0)
Regulation of MOG p35–55 induced EAE by gamma delta T-cells (1998) (0)
Immune Regulatory Mechanisms involved in IL-27 induced Tolerogenic myeloid DCs (P5.229) (2015) (0)
Natalizumab in relapsing multiple sclerosis: appropriate patient selection, management guidelines, and a diagnostic algorithm for the differential diagnosis of new neurologic signs or symptoms (2006) (0)
Assessment of Microglial Activation in Alzheimer Disease Using 18F-PBR06 PET. (2023) (0)
Methods for immunomodulation (2004) (0)
Method of treating or preventing autoimmune uveoretinitis in mammals (1990) (0)
Unraveling the regulatory role of NK cells on T-cell effector functions: Implications for CNS autoimmunity (2014) (0)
Gene-activation during monoclonal antibody mediated demyelination in Lewis rats: Cloning of cDNA by subtractive hybridization (1987) (0)
Long-term quality of life associated with a chemotherapy-based regimen for newly diagnosed central nervous system germ cell tumors: The first international cooperative trial (2002) (0)
Faculty Opinions recommendation of Intrinsic epileptogenicity of cortical tubers revealed by intracranial EEG monitoring. (2012) (0)
Impaired counter-autoimmune mechanisms correlated with immaturation of the neonatal galt and associated with systemic priming rather than tolerance to MBP (1991) (0)
29 Nasal Delivery of Anti-CD3 Antibody Suppresses Murine Lupus by Inducing IL-10 Producing Foxp3+CD4+CD25−LAP+ Regulatory T Cells (2007) (0)
Acquired tolerance to EAE by intrathymic injection of MBP peptides: Role of thymic dendritic cells (1994) (0)
F.23. A Panel of Immunologic Biomarkers Can Discriminate Between Patients with Multiple Sclerosis and Healthy Individuals (2008) (0)
IL-12: immunological staging of multiple sclerosis and measure of response to therapy (2001) (0)
Assessment of clinical definitions of conversion of relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis (P4.402) (2017) (0)
Ancestral risk modification for multiple sclerosis susceptibility detected across the Major Histocompatibility Complex in a multi-ethnic population (2022) (0)
Epileptogenic but MRI-normal perituberal tissue in Tuberous Sclerosis Complex contains tuber-specific abnormalities (2015) (0)
Poster Abstract #14: Magnetic Resonance Disease Severity Scale (MRDSS) Predicts Clinical Progression in Multiple Sclerosis (2008) (0)
Transcriptional Regulation of IL-10-producing Regulatory Type 1 Cells (2010) (0)
Multiple Sclerosis Therapeutics: Use of immunosuppressants to treat multiple sclerosis (2011) (0)
An Observational Comparison Of Natalizumab & Fingolimod Using JCV Serology To Randomize Therapy (P7.205) (2014) (0)
Abstract #6: Magnetic Resonance Disease Severity Scale (MRDSS) for Patients with Multiple Sclerosis: A Longitudinal Study (2010) (0)
OR.102. The CD58 Pathway is Implicated in MS Susceptibility (2008) (0)
Correction to: Clinical trial-ready patient cohorts for multiple system atrophy: coupling biospecimen and iPSC banking to longitudinal deep-phenotyping. (2022) (0)
Oral toleralization to keyhole limpet hemocyanin in humans (1991) (0)
Chapter 72 – Multiple Sclerosis (2013) (0)
Improved repressor regulation of autoimmune diseases by oral or enteral administration of autoantigens. (1991) (0)
Oral Tolerance (2009) (0)
When nerves break down (2004) (0)
Treatment of autoimmune uveoretinitis in humans (1990) (0)
MRI Characteristics of Malignant Multiple Sclerosis (S50.001) (2012) (0)
Protein Degradome of Spinal Cord Injury: Biomarkers and Potential Therapeutic Targets (2020) (0)
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 25-1986. A 24-year-old woman with a three-month history of progressive mental deterioration. (1986) (0)
of Low Dose Oral Tolerance Costimulation Is Required for the Induction B7.2 (CD86) But Not B7.1 (CD80) (1999) (0)
Sa.43. Role of the HLA DRB1*1501 Risk Haplotype in the Expression of Clinical and Radiographic Phenotypes of Multiple Sclerosis (2006) (0)
Identification of Responders to Glatiramer Acetate in MS with Antigen Arrays (S11.002) (2013) (0)
Defective Induction of IL-27-Mediated Immunoregulation by Myeloid DCs in Multiple Sclerosis (2023) (0)
Acute microglia ablation induces neurodegeneration in the somatosensory system (2018) (0)
Subject Index Vol. 22, 1995 (1995) (0)
Comprar Multiple Sclerosis. Diagnosis And Therapy | Howard L. Weiner | 9780470654637 | Wiley (2012) (0)
Treatment with a Fullerene Derivative (ABS-75) Reduces Disease Progression and Axonal Loss in MOG-induced Progressive EAE in NOD Mice (2007) (0)
AHR Controls the Production of Mucosal IL-22 by CD4+ T Cells and NK Cells (2010) (0)
Correspondence concerning “Cerebellitis as a neurosurgical disease in pediatrics” by Goethe EA, LoPresti M, Bertot B, Lam S. J Clinical Neurosci (2021;85:57-63) (2021) (0)
SUPPLEMENTARY INFORMATION MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the CEBP-PU.1 pathway (2010) (0)
What Have We Learned From Magnetic Resonance Imaging Studies (2017) (0)
Elevated levels of soluble HLA class I in the serum of multiple sclerosis patients (1994) (0)
Innovation and clinical progress in oral tolerance. (2023) (0)
The history of neurosurgery at Baylor College of Medicine. (2021) (0)
Human gut derived Anaerotruncus colihominis ameliorates experimental autoimmune encephalomyelitis (2021) (0)
Autoimmune Encephalomyelitis : Studies with TCR V / 3 8 . 2 Transgenic Mice (2003) (0)
Cutting edge: prevention of autoimmune diabetes by homologous recombination of MHC class I region in NOD mouse (1999) (0)
Gamma-Delta T Cells Promote Oral Tolerance Via a Microbiota-Modulating Micro-RNA (2021) (0)
Antigen in TCR-Transgenic Mice Lymphoid Tissue (GALT) Following Oral In Situ Immune Response in Gut-Associated (1998) (0)
Treatment of autoimmune diseases by administration of autoantigen in the form of aerosol (1990) (0)
SUPPLEMENT - EARLY GLIAL DYSFUNCTION Tuberous sclerosis: A primary pathology of astrocytes? (2008) (0)
Diffusional Kurtosis Imaging Assessment of Tuberous Sclerosis Complex (2009) (0)
Association of Serum Neurofilament Biomarker Levels with Quality of Life and Healthcare Utilization in Patients with Multiple Sclerosis (1852) (2020) (0)
High-Fat Diet Causes Rapid Loss of Intestinal Group 3 Innate Lymphoid Cells Through Microbiota-Driven Inflammation (2022) (0)
Optic Pathway Gliomas: Part II—Management (2012) (0)
Regulation of Human CD8 T Cells by IL-27 (2010) (0)
Methods of treating autoimmune uveoretnitis in humans (1990) (0)
IDENTIFICATION O F A HEMAGGLUTININ-SP ECIFIC IDIOTYPE A SSOCIATED W ITH R EOVIRUS R ECOGNITION SHARED BY LYMPHOID A ND N EURAL C ELLS* (1982) (0)
Th 2-Skewing Adjuvant Administration of an Emulsome-Based Regulatory T Cells and Is Enhanced by + Is Associated with Induction of LAP Attenuates Collagen-Induced Arthritis That Mucosal Anti-CD 3 Monoclonal Antibody (2010) (0)
139 Outcome of Stereotactic Laser Ablation of Primary Brain Tumors in Children (2017) (0)
Evolución neonatal adversa asociada con la administración prenatal de dexametasona, en comparación con la betametsona (2006) (0)
Microbial triggers for inflammatory disease (SY6-2) Chairpersons: Kiyoshi Takeda, Hilde Cheroutre (2010) (0)
Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation (2015) (0)
Temporal Lobe Epilepsy Surgery (2020) (0)
Reply to “Detecting oxysterols in the human circulation” (2011) (0)
Cell type- and state- resolved immune transcriptomic profiling identifies glucocorticoid-responsive molecular defects in multiple sclerosis T cells (2022) (0)
Identification of a unique TGF-β–dependent molecular and functional signature in microglia (2013) (0)
Serum microRNAs Are Related to Brain MRI Lesions and Atrophy in Patients with Multiple Sclerosis (P4.140) (2016) (0)
Cranial vault deformity and intracranial hypertension secondary to cephalic molding at delivery: a case and its management. (1999) (0)
Clinical Research in Neurology (2017) (0)
The precise mechanism of neutralization of viruses by antibody is at present (2003) (0)
Antigen driven bystander suppression of acute and relapsing EAE following oral tolerization to MBP: Immunoregulatory pathway dependent on TGF-β (1991) (0)
Longitudinal Study of Disease Burden and Complications in a Cohort of Multiple Sclerosis Patients over the Age of 65. (2019) (0)
Abstract 17477: NCKAP1L: A Novel Target Gene Linked to Survival in Pulmonary Arterial Hypertension Patients (2017) (0)
Platelets promote pathogenic T cell differentiation in MS and EAE (2014) (0)
Targeting of Peripheral Innate Immunity by Nasal Proteosome-Based Vaccine To Treat Alzheimer's Disease (P01.019) (2013) (0)
Maximizing the subtonsillar transcerebellomedullary approach to suprasellar cistern: how I do it (2021) (0)
Production by Human CD 4 IL-27 Is a Key Regulator of IL-10 and IL-17 (2009) (0)
O1-06-08 Activation of microglia by nasal vaccination with a proteosome based adjuvant and glatiramer acetate clears a-beta in an antibody independent fashion in a mouse model of Alzheimer’s disease (2006) (0)
469 The Role of Social Determinants of Health in Child Mortality and Survival Following Abusive Head Trauma (2022) (0)
Translational Therapies for Immune-based Disorders Review Series Guest (2008) (0)
TrbK controls astrocyte-driven oligodendrocyte copper poisoning (2021) (0)
CHAPTER 85 – “Omics” in the Study of Multiple Sclerosis (2009) (0)
Quantitative MRI study of Pineal Gland in MS. (2016) (0)
Immunosuppression with high-dose I.V. cyclophosphamide and acth in progressive multiple sclerosis Cumulative experience in 100 patients (1987) (0)
Optic Pathway Gliomas: Part I—Epidemiology and Presentation (2012) (0)
Corrigendum to “Neuroprotection by IL-10 producing MOG CD4+ T-cells following ischemic stroke” [J Neurol Sci 233 (2005) 125–132] (2013) (0)
Identification of a Unique Microglial Signature in Mice (S50.001) (2013) (0)
Activated T-Cells and Antigen Reactivity in the Cerebrospinal Fluid and Blood of Patients with Multiple Sclerosis (1987) (0)
Dysregulation of the APOE-TGFb pathway leads to loss of the microglial homeostatic signature in neurologic diseases including MS, ALS and AD (2014) (0)
Pediatric Epilepsy (2020) (0)
Disability Improvement with Alemtuzumab vs. Interferon beta-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P07.120) (2013) (0)
Metabolic abnormalities in perituberous tissue : initial results of a proton MR spectroscopy study of pediatric Tuberous Sclerosis Complex (2009) (0)
Editorial: Hypothalamic hamartomas. (2016) (0)
The Role of Ly6C+ Inflammatory Spleen-derived Monocytes in an Animal Model of Brain Ischemia (2010) (0)
Reply (1991) (0)
Connecting up (1988) (0)
Increased expression of the Th1-associated chemokine receptors, CXCR3 and CCR5, by T cells during progressive multiple sclerosis (1998) (0)
Perioperative Procalcitonin in Predicting Infection in Children Undergoing Surgical Procedures. (2020) (0)
Identi ﬁ cation of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN- γ limits IL-17 – mediated autoimmune in ﬂ ammation (2010) (0)
Progressive Multiple Sclerosis Are Activated Myeloid Dendritic Cells in Secondary Innate Immunity in Multiple Sclerosis: (2006) (0)
Results Platelets From Patients With MS Form Aggregates With CD 4 T Cells (2015) (0)
Cell Receptor ( TCR ) Usage Dete ~ aiines Disease Susceptibility In Experimental Autoimmune Encephalomyelitis : Studies with TCR V / 3 8 . 2 Transgenic Mice (2003) (0)
TCF-1 regulates effector T cell responses upon FTY720 treatment in multiple sclerosis (2016) (0)
Enhancement of suppression regulation of autoimmune diseases by oral or enteral administration of autoantigens (1991) (0)
Latency-Associated Protein Surface Localized Glucose-Regulated Gene Induces Cell 1 b Overexpression of TGF-Takatoku (2010) (0)
Current and future therapeutic strategies for autoimmune demyelinating diseases (1991) (0)
Multiple sclerosis: Neuroimmune crosstalk and therapeutic targeting (2023) (0)
Microglial signatures and their role in health and disease (2018) (0)
Identiﬁcation of genetic loci associated with paralysis, inﬂammation and weight loss in mouse experimental autoimmune encephalomyelitis (2001) (0)
A Nasal Anti-CD3 Vaccine Treats A Model Of Secondary Progressive MS By Inducing IL-10 Dependent T Regulatory Cells And Regulating CNS Innate Immunity (S14.004) (2014) (0)
Abstracts from ASENT 2004 Annual Meeting March 11–13, 2004 (2004) (0)
Adipokine Levels in Relapsing and Progressive Forms of Multiple Sclerosis (P02.077) (2012) (0)
Fecal (micro) RNA Isolation. (2020) (0)
Oral autoantigenholdigt preparation (1989) (0)
Treatment of multiple sclerosis and other autoimmune diseases by oral tolerance to autoantigens (1995) (0)
The microbiota restrains neurodegenerative microglia in a model of amyotrophic lateral sclerosis (2022) (0)
Is Associated with Induction of LAP Attenuates Collagen-Induced Arthritis That Mucosal Anti-CD3 Monoclonal Antibody (2010) (0)
Microbiota Signaling Pathways that Influence Neurologic Disease (2018) (0)
Clinical Trial-Ready Patient Cohorts for Multiple System Atrophy: Coupling Biospecimen and iPSC Banking to Longitudinal Deep-Phenotyping (2022) (0)
Imaging of the immune system in multiple sclerosis patients using somatostatin (1998) (0)
A Phenome-wide Examination Uncovers the Comorbidity Burden in Severe Multiple Sclerosis (P1.118) (2015) (0)
Increasing the down-regulation of autoimmune diseases by oral or enteral administration of autoantigens (1991) (0)
F.34. Changes in the CD8dimCD4- Cell Population Parallel Disease Activity in Treated Multiple Sclerosis Subjects (2008) (0)
1128 Sleep Apnea and Periodic Limb Movements are Highly Prevalent in Patients With Multiple Sclerosis (2020) (0)
Systematic evaluation of RNA quality, microarray data reliability and pathway analysis in fresh, fresh frozen and formalin-fixed paraffin-embedded tissue samples (2018) (0)
Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients (2022) (0)
Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39 (2019) (0)
Glatiramer Acetate Autoimmune Encephalomyelitis by Oral Th2 Bias and Enhances Suppression of Promotes a t Cutting Edge: Oral Type I IFN-Howard (2002) (0)
Gamma-delta T cells modulate the microbiota and fecal micro-RNAs to maintain mucosal tolerance (2023) (0)
Immune Dysregulation in Multiple Sclerosis (2016) (0)
microRNA Expression in Peripheral Blood Monocytes Is Altered in Both Relapsing and Progressive Forms of Multiple Sclerosis (S40.003) (2012) (0)
CLA-supplemented diet accelerates experimental colorectal cancer by inducing TGF-β-producing macrophages and T cells (2018) (0)
γδ T cells control humoral immune response by inducing T follicular helper cell differentiation (2018) (0)
Immunogenicity of class II MHC allopeptides in vivo (1992) (0)
CCR 2-Deficient Mice Monocyte Chemoattractant Protein-1-and Induction of Low Dose Oral Tolerance in (2003) (0)
Inhibition of T Cell Responses by Activated Human CD8+ T Cells is Mediated by Interferon-y and is Defective in Chronic Progressive Multiple Sclerosis (2004) (0)
Estimating the association between physical activity and health-related quality of life in individuals with multiple sclerosis. (2022) (0)
Evaluation of the revised 2013 MS clinical course definitions in the CLIMB real world cohort (P5.190) (2015) (0)
765 A Non-Toxic Aryl Hydrocarbon Receptor Agonist Suppresses Colitis Driven by Human T-Cells in Human Leukocyte Antigen-DR1 Transgenic Humanized Mice (2016) (0)
Giant Symptomatic Meningocele as a Delayed, Adult Complication of Lipomyelomeningocele. (2019) (0)
Erratum to “Membrane bound IL-15 is increased on CD14 monocytes in early stages of MS” [J. Neuroimmunol. 195 (2008)135–139] (2009) (0)
Transcriptional signature of human pro-inflammatory TH17 cells identifies reduced IL10 gene expression in multiple sclerosis (2017) (0)
Cellular Immunological Studies with Monoclonal Antibodies in Neurological Diseases (1982) (0)
Mechanisms of Acquired Thymic Tolerance in Experimental Autoimmtme Encephalomyelitis: Thymic Dendritic-enriched Cells Induce Specific Peripheral T Cell Unresponsiveness In Vivo By Samia J. Khoury,* Lorenzo Gallon, Wanjun Chen,* (1995) (0)
Immunologic and Tolerogenic Aspects of Amyloid Beta-Peptide: Implications for the Pathogenesis and Treatment of Alzheimer’s Disease (2003) (0)
Gene Activation During Experimental Allergic Encephalomyelitis (1988) (0)

This paper list is powered by the following services:

Other Resources About Howard L. Weiner

en.wikipedia.org

What Schools Are Affiliated With Howard L. Weiner?

Howard L. Weiner is affiliated with the following schools:

Image Attributions

Image Source for Howard L. Weiner